Archived Medical News Stories

RSSArchived Drug Trial News Stories - 2009

Date Title Comments Rating
2009-12-31 FDA evaluates Phase III randomized trial in acute myeloid leukemia 0 None
2009-12-30 Santarus submits rifamycin SV MMX IND to the FDA 0 None
2009-12-30 Phase 3 trial of figitumumab discontinued by Pfizer 0 None
2009-12-29 Advaxis reports 3-year survival data from its ADXS11-001 Phase I trial for cervical cancer 0 None
2009-12-29 Promising results from Soligenix' RiVax vaccine against ricin toxin 0 None
2009-12-28 SVA submits the first clinical trial application for HFMD vaccine in China 0 None
2009-12-24 SemBioSys Genetics' Apo AI(Milano) program progress update 0 None
2009-12-24 Forest Laboratories acquires additional rights to NXL 104 beta-lactamase inhibitor 0 None
2009-12-24 Merck discontinues MK-1903 niacin receptor agonist development program with Arena Pharmaceuticals 0 5
2009-12-23 Synta Pharmaceuticals initiates STA-9090 Phase 2 clinical trial for GIST 0 None
2009-12-23 Positive results from Alimera Sciences' Iluvien FAME trial for DME 0 4.5
2009-12-23 Rigel Pharmaceuticals announces milestone payment from Daiichi Sankyo 0 None
2009-12-23 Compugen, Pfizer enter into multi-target collaboration 0 None
2009-12-23 ARCA biopharma submits Gencaro trial protocol for review under the FDA’s SPA process 0 None
2009-12-23 US Phase 2 clinical trial of RVX-208 commenced by Resverlogix 0 None
2009-12-22 Eritoran well tolerated in Phase II trial for severe sepsis 0 None
2009-12-22 Effectiveness of Genfit’s GFT505 clinical drug candidate questioned 0 None
2009-12-22 Study results of CSL’s pandemic H1N1 2009 vaccine published in JAMA 0 None
2009-12-22 DSM BioSolutions to manufacture Mayoly Spindler's 'MS1819' lipase biotherapeutic 0 None
2009-12-22 LEO Pharma announces positive results for two Phase III AK clinical trials 0 None
2009-12-21 Results from Phase I trial of Bryan Oncor's targeted radiopharmaceutical therapy reported 0 None
2009-12-21 Oxford Finance to provide Titan Pharmaceuticals a $3M term loan 0 None
2009-12-21 Neurocrine to advance its NBI-98854 VMAT2 Inhibitor into a multiple repeated dose Phase 1 study 0 None
2009-12-21 Positive interim results from Idera Pharmaceuticals' IMO-2125 Phase 1 clinical trial for HCV 1 5
2009-12-21 Teva Pharmaceutical Industries, OncoGenex Pharmaceuticals announce collaboration in cancer therapy 0 None
2009-12-21 OncoGenex Pharmaceuticals to pay Isis Pharmaceuticals $10M for license of OGX-011 to Teva Pharmaceutical Industries 0 3
2009-12-21 CPEX Pharmaceuticals completes enrollment in Nasulin Phase 2a clinical trial 0 None
2009-12-21 Eli Lilly, Incyte announce collaboration for development and commercialization of INCB28050 oral inhibitor 0 None
2009-12-21 Intra-Cellular Therapies announces results of its ITI-007 antipsychotic drug Phase I study 0 2.3
2009-12-21 Positive interim results from Medicago's H5N1 vaccine Phase I human clinical trial 0 None
2009-12-21 Soligenix commences SGX201 Phase 1/2 clinical trial for acute radiation enteritis prevention 0 None
2009-12-21 Preliminary results from Phase III study of afamelanotide in EPP announced 1 None
2009-12-18 Taro Pharmaceutical Industries initiates its T2007 non-sedating barbiturate compound Phase I clinical trials 0 None
2009-12-18 U.S. health officials announce shift in focus of prep trial in Botswana 0 None
2009-12-18 PolyMedix completes first two segments of its PMX-30063 antibiotic drug candidate Phase 1B study 0 None
2009-12-18 Flamel Technologies initiates IFN-alpha-2b XL Phase 2a clinical trial for HCV 0 None
2009-12-18 Initial data from REVLIMID Phase III trial in multiple myeloma patients announced 0 None
2009-12-18 Phase 2 clinical study of STA-9090 in NSCLC initiated 0 None
2009-12-18 ARIAD Pharmaceuticals completes enrollment of patients for Phase 3 clinical trial of ridaforolimus 0 None
2009-12-17 Arno Therapeutics announces dosing of first patient in Phase II clinical study of AR-67 0 None
2009-12-17 Update on Phase 2 clinical trial of oral interferon announced by Amarillo Biosciences 0 None
2009-12-17 AlphaRx, Venturepharm sign supply agreement for ARX1088's API 0 None
2009-12-17 Positive results from DURECT's Phase IIb POSIDUR clinical trial for post-surgical pain 0 None
2009-12-17 Alcon increases its financial support for NovaBay Pharmaceuticals' research and development efforts 0 None
2009-12-17 Anadys Pharmaceuticals reports positive 4-week results from its ANA598 Phase II study for HCV 0 None
2009-12-17 BDSI's BEMA Buprenorphine Phase 2 study meets primary efficacy endpoint 0 None
2009-12-17 Sanofi Pasteur uses PHT’s LogPad System and StudyWorks online portal for its Phase II trial 0 None
2009-12-17 Roche discloses results of two of eight taspoglutide T-emerge phase III studies in diabetes patients 0 2
2009-12-17 Top-line efficacy and safety results from Phase 2b clinical trial of XIAFLEX announced 0 None
2009-12-16 Phase 3 registration clinical trial for perifosine initiated by Keryx Biopharmaceuticals 1 None
2009-12-16 NanoBio, GSK partner to develop and commercialize novel cold sore treatment compound 0 1
2009-12-16 Nanotherapeutics acquires Ramoplanin clinical program from Oscient Pharmaceuticals 0 None
2009-12-16 ChemoCentryx commences enrollment in CCX354 Phase 2 clinical trial for RA 0 None
2009-12-16 Advanced Life Sciences Holdings' Restanza promising against tularemia 0 None
2009-12-16 Keryx Biopharmaceuticals initiates Phase 3 registration clinical trial for perifosine 0 None
2009-12-16 Positive results from Onset Therapeutics' BenzEFoam Emollient Foam skin moisturization study 0 None
2009-12-16 Xencor's initiation of novel monoclonal antibody human clinical trial triggers milestone payment from Pfizer 0 None
2009-12-16 Naurex' GLYX-13 demonstrates antidepressant-like and anxiolytic-like activity without CNS-related side effects 0 None
2009-12-16 Naurex commences dosing in its GLYX-13 Phase I clinical trial for treatment-resistant depression 0 None
2009-12-16 Positive results from Auxilium Pharmaceuticals' XIAFLEX Peyronie's disease phase IIb trial 1 None
2009-12-16 Patients involved in Novelos Therapeutics' pivotal Phase III trial live longer than expected 0 5
2009-12-16 Cancer Research UK's phase I trial results of CHT25 published in Clinical Cancer Research 0 None
2009-12-16 ThromboGenics completes enrollment in second microplasmin Phase III trial 0 None
2009-12-15 DSMB approves advancement of PLX-PAD to intermediate dose level in Phase I clinical trial for CLI treatment 0 None
2009-12-15 BioAlliance Pharma SA to enter Phase II clinical trial for clonidine Lauriad and Phase I clinical trial for AMEP 0 None
2009-12-15 Advaxis to collaborate with GOG in Phase II clinical trial of ADXS11-001 0 None
2009-12-15 Positive results from study comparing exenatide once weekly to BYETTA 0 3
2009-12-15 Femta Pharmaceuticals, Lonza Group collaborate in cGMP production of FM101 antibody 0 None
2009-12-15 Can-Fite BioPharma to commence Glaucoma Phase II clinical study in Israel 0 4
2009-12-15 University of Wisconsin IRB approves GenSpera's G-202 Phase I study for cancer 0 None
2009-12-15 Encouraging results from DAVANAT in combination with chemotherapies and biologics 0 None
2009-12-15 Celgene announces positive data from its apremilast Phase IIb study for plaque-type psoriasis 0 None
2009-12-15 Lytix Biopharma AS receives approval to commence Phase I clinical trials of Oncopore 0 None
2009-12-15 QLT commences enrollment in QLT091001 Phase Ib trial of LCA pediatric patients 0 None
2009-12-15 Seattle Genetics announces collaboration to globally develop and commercialize brentuximab vedotin 0 None
2009-12-15 Molecular Partners closes its CHF 46 million Series B equity investment round 0 None
2009-12-15 Update on new clinical developments and other initiatives related to Ceplene 0 None
2009-12-15 Modifications to Phase II study AD201 and open label extension study AD251 for ELND005 notified 0 None
2009-12-15 Phase III clinical trial evaluating darusentan misses its co-primary efficacy endpoints 0 None
2009-12-15 Updated clinical data from Phase 2 study evaluating oral ridaforolimus presented 0 None
2009-12-14 Oncolytics Biotech develops REOLYSIN for patients affected by hard-to-treat cancers 0 3.5
2009-12-14 Genentech announces Phase III study of Avastin in women treated with chemotherapy for advanced breast cancer 0 5
2009-12-14 AVAC: MDP 301 effectiveness trial finds no evidence that PRO 2000 microbicide reduces HIV infection 0 None
2009-12-14 Pfizer announces results from studies evaluating neratinib 0 None
2009-12-14 Results from Phase 2 trial evaluating Nexavar with capecitabine and paclitaxel presented 0 None
2009-12-14 Tulane Cancer Center starts randomizing patients in phase III clinical study of Alpharadin 1 5
2009-12-14 Combination therapy improves overall survival in women with advanced breast cancer 0 None
2009-12-14 Ipsen announces preliminary results of phase I trial in metastatic breast cancer with BN83495 0 None
2009-12-14 Genentech announces positive results from Phase II study of T-DM1 1 None
2009-12-14 Incyte announces positive results from ongoing Phase I/II clinical trial for INCB7839 0 None
2009-12-14 ImmunoGen announces the presentation of positive trastuzumab-DM1 clinical data 0 None
2009-12-13 Positive Phase 2 study results of CDX-011 reported by Celldex Therapeutics 0 None
2009-12-13 Positive interim results of ARRY-380 in Phase 1 trial announced 0 None
2009-12-13 Clinical trial of 2009 H1N1 influenza vaccine 0 None
2009-12-12 Enrollment of patients for Phase IIb clinical trial of WBI-1001 commenced 0 None
2009-12-12 Phase 1 clinical trial of iCo-007 demonstrates positive safety profile 0 None
2009-12-11 Phase 2 pivotal trial of AC220 initiated by Ambit Biosciences 0 None
2009-12-11 Zevalin clinical data presented at 2009 ASH meeting 0 None
2009-12-11 Genentech terminates dacetuzumab collaboration agreement with Seattle Genetics 0 1
2009-12-11 Pfizer announces IES analysis of Aromasin in breast cancer recurrence 0 None
2009-12-11 ThromboGenics initiates Phase II trial of microplasmin for wet AMD 0 None
2009-12-11 Genentech and Biogen Idec report positive outcome from ocrelizumab-MTX combination study in RA 0 None
2009-12-11 Tasigna demonstrates greater efficacy over Gleevec in chronic Ph+ CML patients 0 None
2009-12-11 Initiation of multi-national Phase III study of Stimuvax announced 0 1
2009-12-11 DMC recommends Novartis and Nordic Bioscience to continue oral calcitonin Phase III studies 0 None
2009-12-11 Fulvestrant 500 mg reduces risk of disease progression in women with metastatic breast cancer 0 None
2009-12-10 Positive results from BioAlliance Pharma's acyclovir Lauriad phase III trial 0 None
2009-12-10 FDA approves Azaya Therapeutics' Taxotere for Phase I clinical study 0 None
2009-12-10 DMC recommends Emisphere Technologies' to proceed with oral calcitonin trial for OP and OA 0 None
2009-12-10 Targacept commences TC-5619 Phase 2 study of cognitive dysfunction in schizophrenia 0 None
2009-12-10 Merck commences Stimuvax Phase 3 trial in Asian patients with NSCLC 0 1
2009-12-10 Schizophrenia: Once-monthly INVEGA SUSTENNA not inferior to bi-weekly RISPERDAL CONSTA 0 5
2009-12-10 Second-quarter fiscal 2010 results announced by Peregrine Pharmaceuticals 0 None
2009-12-10 Fourth-quarter and full year fiscal 2009 results announced by Biodel 0 None
2009-12-10 Immune-based treatment promising for AD 0 None
2009-12-10 Rituxan improves patients with previously untreated CLL, shows Phase III study CLL8 0 None
2009-12-10 Results from Tulip PETAL Study of elagolix announced by Neurocrine Biosciences 0 None
2009-12-10 Initiation of dose-finding study to evaluate safety and efficacy of MP4OX treatment 0 None
2009-12-10 Second pivotal Phase 3 trial to evaluate investigational Lp-PLA2 inhibitor darapladib initiated 0 None
2009-12-09 Additional data from ALS patients enrolled in confirmatory Phase III STAR trial announced 0 None
2009-12-09 Roche to present data on its Herceptin, Avastin and T-DM1 studies at CTRC-AACR Symposium 0 None
2009-12-09 RegeneRx Biopharmaceuticals completes Phase I trial evaluating systemic administration of RGN-352 0 None
2009-12-09 Watson Pharmaceuticals' RAPAFLO demonstrates safety and tolerability in BPH treatment 0 None
2009-12-09 Osteologix to file an European Marketing Application for its NB S101 strontium therapy 0 None
2009-12-09 Preliminary data from Phase 2 clinical trial of ZFP Therapeutic program presented 0 None
2009-12-09 Clinical results from Phase 2 study of KNS-760704 presented by Knopp Neurosciences 0 5
2009-12-09 Clinical trial results demonstrate greater efficacy of nilotinib over imatinib for Ph+ CML 0 None
2009-12-09 VERTICAL Phase II trial results for NHL released 0 5
2009-12-09 Recruitment complete in Oxagen's OC000459 IIb clinical trial for asthma 0 None
2009-12-09 Memgen announces positive clinical data of ISF35 with chemotherapy 0 None
2009-12-09 TGen and Scottsdale Healthcare test PHA-848125ac drug for thymic cancer 0 None
2009-12-09 University of Texas launches phase II clinical trial to test stem-cell-based therapy on injured heart muscle 0 None
2009-12-09 Data evaluating combination therapy with REVLIMID and rituximab in patients with NHL presented 0 None
2009-12-09 Mozobil with chemotherapy may have a therapeutic impact on leukemic cells, reveals study 0 None
2009-12-09 Multiple clinical study results of ABRAXANE to be presented by Abraxis BioScience 0 None
2009-12-09 Phase II clinical trial results of Doxorubicin Transdrug announced 0 None
2009-12-09 GSK updates long-term survival data of BEXXAR Therapeutic Regimen for Non-Hodgkin's lymphoma 0 None
2009-12-09 Neoprobe completes Phase 3 Lymphoseek clinical trial on breast cancer patients 0 None
2009-12-08 Updated clinical data of Calistoga Pharmaceuticals’ delta selective PI3K inhibitor presented 0 None
2009-12-08 Micromet presents final data from its blinatumomab Phase 2 study for ALL 0 None
2009-12-08 The National Fragile X Foundation awards $100,000 grant for study of minocycline in FXS children 0 None
2009-12-08 Updated data from Allos Therapeutics' ongoing FOLOTYN study 0 None
2009-12-08 Hemaquest Pharmaceuticals' HQK-1001 holds promise for sickle cell disease and beta thalassemia 0 3
2009-12-08 Hemodynamic Therapeutics' HTI-101 clinical study for treatment-resistant hypertension meets primary endpoint 0 None
2009-12-08 Interim data from Geron's GRNVAC1 phase II trial for AML presented 0 None
2009-12-08 Encouraging results from Semafore Pharmaceuticals' SF1126 Phase I dose-escalation trial for myeloma 0 None
2009-12-08 Clinical trial results of VELCADE based combinations for MM to be presented at the ASH meeting 0 None
2009-12-08 Phase 2 study of carfilzomib shows promising results in patients with refractory multiple myeloma 0 None
2009-12-08 Study data of REVLIMID-dexamethasone combination therapy for high-risk smoldering multiple myeloma 0 None
2009-12-08 Enrollment of patients for Phase I/IIa clinical study of Interleukin-7 commenced 0 5
2009-12-08 Positive data from Onconova Therapeutics' ON 01910.Na trial for advanced MDS 0 5
2009-12-08 Positive data from ARIAD Pharmaceuticals' ongoing AP24534 study in advanced hematological cancer patients 0 None
2009-12-08 SOLESTA pivotal study meets primary endpoints for fecal incontinence treatment 0 None
2009-12-08 Phase III CLL8 trial shows Rituxan plus FC chemotherapy improves patients with CLL 0 None
2009-12-08 Ambit Biosciences presents study results of its AC220 FLT3 inhibitor for AML 0 None
2009-12-08 Neovacs announces initiation of a Phase IIa clinical study of TNFα Kinoid immunotherapy 0 None
2009-12-08 Two abstracts describing preclinical studies with GMI-1070 selected for oral presentations 0 None
2009-12-08 ImmunoGen's SAR3419 holds hope for B-cell non-Hodgkin’s lymphoma 0 None
2009-12-08 Gentium presents evaluation results of Defibrotide for VOD at the ASH conference 0 None
2009-12-08 Study results comparing REVLIMID regimen to stem cell transplant in multiple myeloma patients 0 None
2009-12-08 Galapagos NV receives milestone payment to initiate Phase I clinical trial of GLPG0555 drug 0 None
2009-12-08 Additional data from ChemoCentryx' study of Traficet-EN in Crohn's disease patients 0 None
2009-12-08 Potentially promising data from Phase I/II study of elotuzumab presented at ASH 2009 0 None
2009-12-08 PolyMedix to present data on its heptagonist compounds 0 None
2009-12-08 Amgen announces results from first Phase 1/2 study of Nplate 0 None
2009-12-08 CAM314 randomized Phase 3 clinical trial results released 0 5
2009-12-08 Data from two phase Ib clinical trials of dacetuzumab for DLBCL reported 0 None
2009-12-08 Phase II clinical trial results reveal positive effects of omacetaxine against CML 0 None
2009-12-08 Results of preclinical studies evaluating AC220 to be presented at ASH annual meeting 0 None
2009-12-08 Carfilzomib shows noteworthy responses and low side effects among multiple myeloma patients 0 None
2009-12-08 Biogen Idec's BG-12 achieves key milestones in clinical trials for MS and RA 0 None
2009-12-08 Phase 1 study results of TRU-016 in patients with CLL announced 0 None
2009-12-07 Results from CytRx's Phase 2 STAR-1 registration clinical trial for tamibarotene announced 0 None
2009-12-07 Phase 3 results for European efficacy trial Z-036 in BPH with cetrorelix pamoate reported 0 None
2009-12-07 New data from Allos Therapeutics' FOLOTYN trial for PTCL 0 None
2009-12-07 Study data of Perifosine + Bortezomib combination in multiple myeloma patients presented 0 None
2009-12-07 Incyte's INCB18424 provides previously unachievable clinical benefits in myelofibrosis patients 0 5
2009-12-07 Interim data from Celator Pharmaceuticals' CPX-351 trial presented at the ASH meeting 0 None
2009-12-07 Synta Pharmaceuticals announces study results of elesclomol 0 None
2009-12-07 Æterna Zentaris reports Phase 3 results of its cetrorelix pamoate Z-036 trial for BPH 0 None
2009-12-07 Encouraging data from Seattle Genetics' phase I trial of brentuximab vedotin 0 None
2009-12-07 Micromet to present new data from its blinatumomab Phase 1 trial at the ASH meeting 0 None
2009-12-07 UCB presents data on Vimpat AED at AES meeting 0 None
2009-12-07 Preclinical and Phase I data for TG-0054 presented by TaiGen Biotechnology 0 None
2009-12-07 Dabigatran etexilate prevents recurrent VTE with less bleeding than warfarin 0 None
2009-12-07 Positive data from Gloucester Pharmaceuticals' ISTODAX study presented at the ASH meeting 0 None
2009-12-07 J&JPRD announces clinical results of new oral anticoagulant therapy for venous thromboembolism 0 None
2009-12-07 Positive clinical data from Phase II study of elacytarabine in patients with AML reported 0 None
2009-12-07 Updated results from phase III EXTEND clinical trial of pixantrone released 0 None
2009-12-07 Phase I/II clinical trial of Multimeric-001 Universal Flu Vaccine successful 0 None
2009-12-07 ChemGenex Pharmaceuticals presents clinical results of Omapro drug at ASH meeting 0 None
2009-12-07 Presentation of preclinical data demonstrating the combination of ISTODAX and Velcade announced 0 None
2009-12-07 Poster summarizing clinical trial data regarding SB-743921 presented by Cytokinetics 0 None
2009-12-07 Researchers explore optimal induction therapies for managing blood cancer 0 None
2009-12-07 VELCADE based regimens are cost-effective for payers and patients, finds study 0 None
2009-12-07 New analyses of data from Allos Therapeutics’ pivotal PROPEL trial of FOLOTYN reported 0 None
2009-12-07 Alexion Pharmaceuticals announces positive data from AEGIS study of Soliris 0 None
2009-12-07 Amgen announces results from three studies on the safety and efficacy of Nplate 0 None
2009-12-07 Updated safety data from Phase 2b 003-A1 study of carfilzomib announced 0 None
2009-12-06 ImmunoGen reports encouraging clinical data of IMGN901 0 None
2009-12-06 Positive final data from Phase 2 study of ISTODAX presented 0 None
2009-12-06 Dabigatran etexilate offers effective therapy to prevent recurrent VTE 0 None
2009-12-06 Bortezomib can improve control of GVHD and immune system recovery 0 None
2009-12-05 Investigators to discuss data presentations on carfilzomib inhibitor at ASH Annual Meeting 0 None
2009-12-05 Oxygen Biotherapeutics commences enrollment in clinical trial of Oxycyte emulsion for TBI 0 None
2009-12-04 Pre-clinical study data of Stemline Therapeutics' IL-3R targeting agents to be presented at the ASH meeting 0 None
2009-12-04 Results from Phase III pivotal study of FIRMAGON presented 0 None
2009-12-04 Pfizer to present study findings from its expanded breast cancer portfolio 0 None
2009-12-04 Preclinical data of Curis' HSP 90 inhibitor published 0 None
2009-12-04 Allos Therapeutics, Idis collaborate in named patient program for FOLOTYN 0 None
2009-12-04 Type 2 diabetics with CAD experience greater antiplatelet activity with prasugrel compared to clopidogrel 0 None
2009-12-04 Genzyme announces reopening of enrollment in its Pompe disease ATAP program 0 None
2009-12-03 Lightlake Therapeutics granted ethical approval for gene testing subjects in obesity treatment trial 0 None
2009-12-03 Last patient visit complete in VIA Pharmaceuticals' Phase 2 FDG-PET trial 0 None
2009-12-03 iCo Therapeutics to present an overview of its iCo-007 VEGF "+" agent at the ISOPT conference 0 None
2009-12-03 Initial positive data from Amira Pharmaceuticals' Phase 1 clinical study of AM461 DP2 antagonist 0 None
2009-12-03 Hyperion Therapeutics commences enrollment in its HPN-100 episodic hepatic encephalopathy trial 0 None
2009-12-03 Update on Celsion's ThermoDox Phase III “HEAT” trial for HCC 0 None
2009-12-03 Tripep receives approval to extend ChronVac-C study 0 None
2009-12-03 More than 80 abstracts highlighting Bristol-Myers Squibb's oncology compound to be presented 0 None
2009-12-03 European Phase III clinical trial of budesonide MMX completes patient enrollment 0 None
2009-12-02 Favorable initial results from Novavax' 2009 H1N1 VLP pandemic influenza vaccine Phase II study 0 None
2009-12-02 FDA grants Fast Track designation for AEterna Zentaris' perifosine 0 None
2009-12-02 Genta to supply Ganite for new CF clinical trial 0 None
2009-12-02 Sepracor to present clinical study data of STEDESA at the 2009 AES meeting 0 None
2009-12-02 New data demonstrating the strength of Novartis' hematology portfolio to be presented 0 None
2009-12-02 University of Texas M.D. Anderson Cancer Center and Stemline Therapeutics enter into research collaboration 0 None
2009-12-02 Updated results from MYTHOS clinical trial of RenalGuard presented at AHA meeting 0 None
2009-12-02 Roche announces results of phase III taspoglutide study in diabetes patients 0 2
2009-12-02 Results from second Phase III placebo controlled study of EXPAREL announced 0 4
2009-12-02 Data from brentuximab vedotin and dacetuzumab programs to be presented by Seattle Genetics 0 None
2009-12-02 New data on pixantrone Phase III trial in non-Hodgkin's lymphoma to be presented 0 None
2009-12-02 Results from ongoing clinical trial of ISF35 to be presented at ASH annual meeting 0 None
2009-12-02 Ohr Pharmaceutical to present interim data from ongoing Phase II clinical trial of OHR/AVR118 0 None
2009-12-01 CRO to run CEL-SCI's upcoming Phase III clinical trial 0 None
2009-12-01 Calistoga Pharmaceuticals to present data on its CAL-101 inhibitor at the 51st ASH meeting 0 None
2009-12-01 Palatin Technologies issued U.S. patent covering its lead heart failure drug candidate 0 None
2009-12-01 Positive results from Ardea Biosciences' ongoing drug-drug interaction study of RDEA594 and febuxostat 0 None
2009-12-01 Bioequivalence and comparable toxicity of ADVENTRX Pharmaceuticals' ANX-514 and Taxotere affirmed 0 5
2009-12-01 Positive data from Provectus Pharmaceuticals' psoriasis and atopic dermatitis trials 0 None
2009-12-01 StemCyte concludes exclusive license and commercialization agreement with Academia Sinica 0 None
2009-12-01 Amgen to present updated data on Nplate at the 2009 ASH meeting 0 5
2009-12-01 Completion of Phase I study of CPSI-2364 announced by Cytokine PharmaSciences 0 None
2009-12-01 University of Navarra Hospital launches clinical trials to assess the efficacy of immunotherapy treatment 0 None
2009-12-01 ChemGenex Pharmaceuticals to present updated clinical data from its clinical trials with Omapro 0 None
2009-11-30 QRxPharma commences Phase 3 pivotal trial of MoxDuo IR 0 None
2009-11-30 Bayer Healthcare Pharmaceuticals commences enrollment in florbetaben Phase III clinical trials 0 None
2009-11-30 NOVAVAX completes patient enrollment in its trivalent seasonal influenza VLP vaccine Phase II study 0 None
2009-11-30 Kiadis Pharma commences enrollment in multinational ATIR study 0 None
2009-11-30 NanoViricides announces filing of its quarterly report with the SEC 0 None
2009-11-30 Micromet to present new results from its blinatumomab study at the ASH meeting 0 None
2009-11-30 Spectrum Pharmaceuticals completes enrollment in apaziquone Phase 3 trial 0 None
2009-11-27 Tripep completes clinical trial of ChronVac-C for Hepatitis C virus treatment 0 None
2009-11-26 Merck to commence MK-6913 phase IIa efficacy trial for treatment of hot flashes/hot flushes 0 None
2009-11-25 Additional data on lubiprostone presented at the GASTRO 2009 UEGF/WCOG meeting 0 None
2009-11-25 Novartis to terminate its research collaboration agreement with Idera Pharmaceuticals 0 None
2009-11-25 Synexus recruits patients to study paediatric vaccine against rotavirus 0 None
2009-11-25 Positive Phase II/III clinical data from ChemoCentryx' PROTECT-1 Traficet-EN trial 0 None
2009-11-25 Clinical data on ImmunoGen's TAP compounds to be presented at the 51st ASH meeting 0 None
2009-11-25 CHMP positive opinion for marketing ELONVA in Europe 0 None
2009-11-25 Ambit Biosciences presents data evaluating FLT3 inhibitor in AML at the 51st ASH meeting 0 None
2009-11-25 EMEA grants orphan drug status for LFB Biotechnologies' recombinant anti-CD20 monoclonal antibody 0 None
2009-11-25 Initiation of Phase II clinical trial to evaluate the efficacy of BN83495 announced 0 None
2009-11-25 Positive efficacy data from Phase 2 study of AEZS-108 announced 0 None
2009-11-24 OmniComm Systems chosen as Beardsworth's preferred EDC provider 0 None
2009-11-24 Ohr Pharmaceutical to develop OHR/AVR118 for cachexia treatment 0 1.5
2009-11-24 CytRx to initiate a multinational Phase 2 clinical trial of its doxorubicin prodrug 0 None
2009-11-24 Positive data from Æterna Zentaris' Phase 2 targeted cytotoxic peptide conjugate study 0 None
2009-11-24 StemCells commences patient recruitment for a Phase I clinical trial of HuCNS-SC in PMD 0 None
2009-11-23 Proteon Therapeutics commences PRT-201 Phase 1/2 clinical study in hemodialysis patients 0 None
2009-11-23 Top-line data from Lexicon Pharmaceuticals' LX1031 Phase 2 study for IBS to be presented 0 None
2009-11-23 Acucela to present data on its ACU-4429 visual cycle modulator for dry AMD 0 None
2009-11-23 Positive interim results from Nereus Pharmaceuticals' plinabulin VDA study for advanced NSCLC 0 4.3
2009-11-23 Phase IIb/III clinical trial results of CINQUIL for pediatric EoE announced 0 1
2009-11-23 Phase 1 data of ARIAD Pharmaceuticals' pan-BCR-ABL inhibitor to be presented at the ASH meeting 0 None
2009-11-23 Provectus Pharmaceuticals announces Phase 1 interim study data of PV-10 for metastatic melanoma 0 5
2009-11-23 Human Genome Sciences commences patient dosing in its HGS1029 inhibitor trial 0 None
2009-11-23 Raptor Pharmaceutical announces Phase 2b results of DR Cysteamine trial 0 None
2009-11-23 Raptor Pharmaceutical announces results of NGX426 clinical trial 0 5
2009-11-23 Enrollment for ongoing phase 2b trial of RG7128 announced 0 None
2009-11-23 Initiation of Phase I/IIa clinical trial of IL-7 announced 0 None
2009-11-20 POZEN commences enrollment in PA32540 phase 3 study 0 None
2009-11-20 Genta announces preliminary results from study of Genasense Injection for advanced melanoma 0 None
2009-11-20 EMEA's CHMP recommends approval of Merck's ELONVA 0 None
2009-11-20 Inovio Biomedical announces positive test results of its consensus influenza vaccines 0 1
2009-11-20 Positive results from recently completed phase II clinical study of ToleroMune therapy announced 0 None
2009-11-20 Data from second positive pivotal study of PSD502 for treatment of PE presented 0 None
2009-11-20 Curemark begins enrolling patients in Phase III clinical trials for CM-AT 0 None
2009-11-19 Aegera Therapeutics commences AEG35156 Phase 2B study for AML 0 None
2009-11-19 Adamas Pharmaceuticals expands its Phase 2 TCAD therapy study for influenza A 0 None
2009-11-19 Altair Therapeutics initiates its IL-4 receptor alpha inhibitor bronchoprovocation phase 2 trial 0 None
2009-11-19 Positive results from Sciele Pharma's second pivotal study of PSD502 for the treatment of PE 0 None
2009-11-19 Interim data from Geron's ongoing imetelstat trial presented at the AACR-NCI-EORTC conference 0 4
2009-11-19 AFFiRiS to commence Phase II trial of its Alzheimer's vaccine candidate 0 None
2009-11-19 Final results from ImmuPharma's Phase IIb trial of LUPUZOR 0 None
2009-11-19 Data from Phase 1 safety study of SB-728-T announced 0 None
2009-11-19 Results from Phase IIa clinical trial evaluating VT-111 reported by Viron Therapeutics 0 None
2009-11-19 Once-a-day dosing clinical study of udenafil for erectile dysfunction completed 0 5
2009-11-19 Interim data from an ongoing phase 1 dose-escalation trial of XL147 reported 0 None
2009-11-18 Key findings from AstraZeneca's phase II studies of ticagrelor 0 None
2009-11-18 Millennium commences Phase I clinical trial for its second-generation proteasome inhibitor 0 None
2009-11-18 Lee's Pharmaceutical granted exclusive license to Jennerex' lead product for HCC 0 None
2009-11-18 CytRx plans Phase 2 clinical trial of its doxorubicin prodrug for advanced gastric cancer 0 None
2009-11-18 Epiphany Biosciences announces results from its valomaciclovir Phase 2b trial for shingles 0 None
2009-11-18 Data on Synta Pharmaceuticals' STA-9090 synthetic inhibitor of Hsp90 presented 0 None
2009-11-18 Recent data from CNSBio's Phase IIa CNSB015 trial to be presented at the Neuropathic Pain conference 0 None
2009-11-18 Clinical Data commences patient enrollment in Stedivaze Phase III trial 0 None
2009-11-18 New pre-clinical data from Alnylam Pharmaceuticals' ALN-VSP program presented 2 None
2009-11-18 Positive results from REVIVE, a phase 3 pivotal study of avanafil announced 0 None
2009-11-18 Phase 2/3 study results of Genzyme's APB announced 0 None
2009-11-18 Pluristem’s PLX-PAD holds promise for critical limb ischemia 0 None
2009-11-18 Findings of Merck's anacetrapib phase IIb study presented at the AHA sessions 0 4
2009-11-18 Updated clinical data from Poniard Pharmaceuticals' picoplatin Phase 2 trial announced 0 None
2009-11-18 NeoPharm presents LE-DT Phase I data at the AACR conference 0 1
2009-11-18 Albireo completes A3309 phase 1b study in patients with chronic idiopathic constipation 0 None
2009-11-18 On-going Phase 2b study conducted by Roche of ITMN-191 modified 0 None
2009-11-18 Review of the results of Phase 2b clinical trial on PASCAL announced 0 None
2009-11-18 Phase 2 clinical trial to test gene therapy treatment for Alzheimer's disease 0 None
2009-11-18 Phase III randomized clinical trial for Alpharadin to be commenced 0 3
2009-11-18 Ongoing Phase 1 study results of XMT-1001 announced by Mersana Therapeutics 0 None
2009-11-17 Genzyme and Isis Pharmaceuticals announce phase 3 study data of mipomersen 0 None
2009-11-17 Alkermes commences phase 2 study of ALKS 33 in patients with alcohol dependence 0 None
2009-11-17 Oncolytics Biotech's REOLYSIN combined with paclitaxel and carboplatin well tolerated for advanced cancers 0 None
2009-11-17 Melanoma Institute director to present Phase 2 study data of PV-10 for metastatic melanoma 0 5
2009-11-17 YM BioSciences presents preclinical results of its small molecule VDA at the AACR-NCI-EORTC conference 0 None
2009-11-17 Anacor Pharmaceuticals commences patient dosing in AN3365 Phase I clinical study 0 None
2009-11-17 ThromboGenics and BioInvent International present phase I results of novel anti-cancer monoclonal antibody 0 None
2009-11-17 Phase II clinical study to evaluate Nanocort commenced 0 None
2009-11-16 Results of Phase III clinical trials of flibanserin for treatment of HSDD in pre-menopausal women released 0 None
2009-11-16 Sequella broadens the licensed therapeutic indications of its SQ109 lead drug candidate 0 None
2009-11-16 Semafore Pharmaceuticals to present SF1126 Phase I data at the 51st ASH meeting 0 None
2009-11-16 Seattle Genetics commences phase I clinical trial of SGN-75 ADC for metastatic renal cell carcinoma 0 None
2009-11-16 Interim data from Hollis-Eden Pharmaceuticals' Apoptone Phase I/II clinical trial presented 0 None
2009-11-16 Alkermes' phase 3 trial of naltrexone XR-NTX meets primary endpoint 0 None
2009-11-16 Aradigm commences patient dosage in Phase 2 trial of novel inhaled ciprofloxacin formulation 0 None
2009-11-16 Findings from post hoc analysis examining emotional lability from Phase 3 study data with Vyvanse announced 0 None
2009-11-16 Aspirin doses have beneficial effects for patients with heart diorders: Study 0 5
2009-11-16 New reversible blood thinner for angioplasty patients not superior over placebo 0 None
2009-11-16 Phase I clinical study for ETC-1002 commenced 0 None
2009-11-13 Axelar AB to present data from ongoing Phase I/II clinical trial of AXL1717 0 1
2009-11-13 Findings on the use of Traumeel S in children with mucositis undergoing SCT presented 0 None
2009-11-13 Abbott to acquire the global rights to PanGenetics' new therapeutic for treatment of chronic pain 0 None
2009-11-13 Results from first-in-man study of NO-donating HMG-CoA Reductase Inhibitor released 0 None
2009-11-13 Mithridion reports progress with its potential oral small-molecule drugs for AD and schizophrenia 0 None
2009-11-13 Positive results from Lexicon Pharmaceuticals' LX1031 Phase 2 study for IBS 0 None
2009-11-13 Adolor commences clinical testing of its oral mu opioid receptor antagonist 0 None
2009-11-12 Senesco's multiple myeloma drug candidate data to be presented at the AACR-NCI-EORTC conference 0 None
2009-11-12 arGentis Pharmaceuticals to commence human clinical evaluation of ARG301 oral altered peptide ligand 0 None
2009-11-12 Tobira Therapeutics presents data on TBR-652 at the European AIDS Conference 0 None
2009-11-12 Keryx Biopharmaceuticals to present KRX-0401 Phase 1/2 clinical trial data at the ASH meeting 0 None
2009-11-12 Trubion Pharmaceuticals to present data on its TRU-016 product candidate at the ASH meeting 0 None
2009-11-12 Data from Phase IIa clinical trial evaluating VT-111 to be presented by Viron Therapeutics at AHA conference 0 None
2009-11-11 Bend Memorial Clinic to begin Phase III lung cancer trial 0 None
2009-11-11 Poniard Pharmaceuticals to present picoplatin Phase 2 trial data at the AACR-NCI -EORTC conference 0 None
2009-11-11 Avanir Pharmaceuticals unveils Star trial results for Zenvia in the treatment of PBA 0 None
2009-11-10 Bristol-Myers Squibb and Alder Biopharmaceuticals collaborate in development of novel biologic for rheumatoid arthritis 0 5
2009-11-10 BioVex completes $70M financing to complete OncoVEX Phase III study 0 None
2009-11-10 Tokai Pharmaceuticals commences TOK-001 Phase 1/2 clinical trial for treatment of castration resistant prostate cancer 0 None
2009-11-10 ImmunoGen to present IMGN901 clinical data at AACR-NCI-EORTC International Conference 0 None
2009-11-09 Emisphere Technologies' key product developments and financial results for the third quarter of 2009 0 None
2009-11-09 ISTA Pharmaceuticals presents additional data from its Bepreve Phase 3 clinical studies 0 None
2009-11-09 Concert Pharmaceuticals commences Phase 1b clinical study of its CTP-518 HIV protease inhibitor 0 None
2009-11-09 Evaluation of DX-88 to resolve symptoms of acute HAE attacks to be presented 0 None
2009-11-09 C1-INH concentrate, an effective therapy to treat acute swelling attacks for HAE 0 None
2009-11-07 Halozyme Therapeutics announces results of its insulin variability study 0 None
2009-11-07 Graceway Pharmaceuticals acquires global rights to Gilead Sciences' GS 9191 anti-proliferative agent 0 None
2009-11-06 GeoVax Labs announces financial results and operational update for the third quarter of 2009 0 None
2009-11-06 Positive interim data from the multicenter randomized Phase II trial of palifosfamide presented 0 None
2009-11-06 Novexel commences comparative study of NXL103 to oral linezolid 0 None
2009-11-05 Helix BioPharma completes enrollment in its Topical Interferon Alpha-2b ano-genital warts clinical program 0 None
2009-11-05 Amgen announces the results for Phase 3 PRIME '203' trial of Vectibix 0 4
2009-11-05 ARIAD Pharmaceuticals' SUCCEED trial of oral ridaforolimus on track 0 None
2009-11-05 Study demonstrates potential of human Serum Amyloid P to block very aggressive fibrotic pathology 0 1
2009-11-05 Raptor Pharmaceutical to present oral AMPA-kainate antagonist data at the neuropathic pain conference 0 None
2009-11-05 Patient enrollment in three late-stage clinical trials completed 0 None
2009-11-04 Warner Chilcott initiates phase III trial of erectile dysfunction drug udenafil 0 None
2009-11-04 Phase III study results on miconazole Lauriad presented by BioAlliance Pharma 0 None
2009-11-04 Acceleron Pharma commences Phase 1 clinical study of its novel angiogenesis inhibitor 0 None
2009-11-04 Medivir presents OPERA-1 Phase IIa trial data at the AASLD meeting 0 None
2009-11-04 Exelixis to present 13 abstracts of its development candidates at the 2009 AACR-NCI-EORTC Conference 0 1
2009-11-04 FDA approves SPA Protocol Amendment for Lucanix Phase III clinical trial 0 None
2009-11-04 ThromboGenics issues business update for the third-quarter of 2009 0 None
2009-11-04 Pfizer and Medivation initiate dimebon trials in patients with Alzheimer’s disease 0 2
2009-11-03 Aerovance enrolls 540 patients in Phase 2b Aerovant clinical trial 0 None
2009-11-03 EntreMed to present its Aurora A/angiogenic kinase inhibitor data at the AACR-NCI-EORTC conference 0 None
2009-11-03 Texas State University researchers to evaluate the effects of ALKA-V6 on animal organisms 0 None
2009-11-03 Seaside Therapeutics commences STX107 Phase 1 clinical trial for Fragile X Syndrome 1 None
2009-11-03 Schering-Plough's Phase III study of Grass Allergy Immunotherapy meets primary endpoint 0 None
2009-11-03 AMRI receives $750,000 milestone payment from Bristol-Myers Squibb 0 None
2009-11-03 Phase 1 study of STX107 for Fragile X syndrome begins 0 None
2009-11-03 Interim data from Schering-Plough's narlaprevir Phase IIa study 0 5
2009-11-03 NUVIGIL improves wakefulness in patients with excessive sleepiness associated with shift work disorder 0 None
2009-11-02 BioVex publishes OncoVEX (GM-CSF) Phase 2 study results 0 None
2009-11-02 Pico-Tesla commences pilot study of its Resonator system for treating type 2 diabetes patients 0 None
2009-11-02 Dendreon submits an amended BLA for PROVENGE active cellular immunotherapy 0 None
2009-11-02 Enzo Biochem announces results of EGS21 clinical trial for treatment of non-alcoholic steatohepatitis 0 None
2009-11-02 EnzymeRx commences patient enrollment in Uricase-PEG 20 phase 1 study 0 1
2009-11-02 Juvaris BioTherapeutics commences enrollment in its JVRS-100 influenza vaccine adjuvant study 0 None
2009-11-02 Avila Therapeutics presents preclinical study data of its AVL-181 HCV protease inhibitor 0 None
2009-11-02 Positive results from Aeterna Zentaris' AEZS-108 Phase 2 study in ovarian cancer patients 0 None
2009-11-02 NIAID awards Pulmatrix $2.2M grant for developing novel influenza therapeutics 0 None
2009-11-02 LRI and lupus organizations congratulate HGS and GlaxoSmithKline for achieving historical landmark 0 None
2009-11-02 Interim data from Bristol-Myers Squibb's BARACLUDE study for chronic hepatitis B patients 0 None
2009-11-02 BMY and ZGen present Phase 1B results for PEG-Interferon lambda in HCV patients 0 None
2009-11-02 HGS and GSK announce results from phase III clinical trials of BENLYSTA 0 None
2009-11-02 BENLYSTA meets primary endpoint in BLISS-76 trial for systemic lupus erythematosus 0 None
2009-11-02 Gilead Sciences to present Viread Phase III clinical trial data 0 None
2009-11-02 Vertex Pharmaceuticals announces study results of telaprevir-based regimen 1 None
2009-11-02 Optimer Pharmaceuticals presents additional data from Phase 3 fidaxomicin study 0 None
2009-10-31 Amgen publishes Phase 3 study results of Aranesp 0 None
2009-10-31 Shire to present key data on ADHD treatments at national psychiatric meeting 0 None
2009-10-31 Shire announces Phase IIIb study results of Daytrana 0 None
2009-10-31 New study results of INTUNIV presented at a major psychiatric medical meeting 0 None
2009-10-31 Schering-Plough receives FDA complete response letter regarding PEGINTRON 0 None
2009-10-31 Quintiles and Eisai partner to develop potential oncology products 0 3
2009-10-31 NovaBay Pharmaceuticals' Aganocide compounds demonstrate potent antifungal activity against onychomycosis 0 None
2009-10-31 Data from multiple clinical and preclinical studies evaluating Hematide announced 0 None
2009-10-30 Bayer HealthCare's Phase II study results of imaging agent florbetaben 0 None
2009-10-30 Sunesis Pharmaceuticals enrolls 113 patients in voreloxin REVEAL-1 trial 0 None
2009-10-30 Idenix Pharmaceuticals reports phase I study results of IDX184 for treating HCV 0 5
2009-10-30 Updated results from Oncolytics Biotech's Phase II study of REOLYSIN presented at CTOS meeting 0 None
2009-10-30 Eisai reports global Phase III study results of eribulin mesylate 0 5
2009-10-30 AcelRx Pharmaceuticals completes End-of-Phase 2 meeting with the FDA for its ARX-01drug/device 0 None
2009-10-30 Isotechnika Pharma develops portfolio of NICAMs with potent cyclophilin inhibition 0 None
2009-10-30 Studies demonstrate that investigational cancer vaccines show encouraging immune response rates 0 5
2009-10-30 Dynavax Technologies announces first clinical data for HEPLISAV investigational hepatitis B vaccine 0 None
2009-10-30 VIVUS presents additional data on Qnexa Phase 3 trials 0 None
2009-10-29 Positive results from Celldex Therapeutics' Phase 1 studies of CDX-1307 cancer vaccine candidate 0 None
2009-10-29 Promedior granted European Orphan Medicinal Product Designation for PRM-151 0 None
2009-10-29 Interim safety review of LEVADEX completed by MAP Pharmaceuticals 0 None
2009-10-29 Positive results from Genta's Phase 3 trial of Genasense 0 2.3
2009-10-29 Protox Therapeutics to present Phase 2 study data of PRX302 for benign prostatic hyperplasia 0 None
2009-10-29 Cempra Pharmaceuticals to present CEM-102 data at the Infectious Diseases Society of America meeting 0 None
2009-10-29 Positive top-line results from Phase IIb clinical trial of cariprazine announced 0 None
2009-10-29 Cardiome Pharmam, Astellas Pharma begin patient enrolment for ACT 5 trial 0 None
2009-10-29 Roche discloses the results of first Phase III clinical study using Taspoglutide 0 2
2009-10-29 CNS Response to present results from depression efficacy study at U.S. Psychiatric and Mental Health Congress 0 None
2009-10-28 Advaxis to enroll patients in Phase II clinical trial of cervical dysplasia following IRB approval 0 None
2009-10-28 New data from CIMZIA WELCOME trial to be presented at the ACG meeting 0 None
2009-10-28 Enrollment for Phase 2 clinical study of NKTR-102 completed ahead of schedule 0 None
2009-10-28 Report on different approaches to reduce Phase II attrition 0 None
2009-10-28 Treatment with TYSABRI reduces the rate of hospitalization in Crohn’s patients 0 None
2009-10-28 Orexigen Therapeutics presents phase 3 trial results of Contrave for treating obesity 0 None
2009-10-28 Arena Pharmaceuticals presents data from its Phase 3 trial of LOrcaserin 0 None
2009-10-28 Data from Phase II clinical trial of NKTR-118 presented 0 None
2009-10-28 Recruitment of Phase II trial of TB-402 completed ahead of schedule 0 None
2009-10-28 POZEN announces Phase I study results of PA65020 0 None
2009-10-28 Mirafit fbcx reduces human body absorption of consumed fat 0 3.5
2009-10-27 Isotechnika Pharma reports voclosporin Phase 2/3 clinical trial results at the AAO meeting 0 None
2009-10-27 Hyperion Therapeutics enrolls first patient in HPN-100 phase III clinical trial for urea cycle disorders 0 None
2009-10-27 NeoPharma submits a Phase II protocol to the FDA for its liposome entrapped docetaxel study 0 None
2009-10-27 First Japanese patient treated in Celsion’s global Phase III ThermoDox HEAT trial 0 None
2009-10-27 Alkermes commences ALKS 37 phase 1 clinical trial for the treatment of opioid-induced constipation 0 None
2009-10-27 Interim results from FREEDOM study announced by NxStage Medical 0 None
2009-10-27 ImmunoCellular Therapeutics presents additional data from its ICT-107 Phase I clinical trial 0 None
2009-10-27 Champions Biotechnology obtains global rights to Tel Aviv University's TAR-1 compound 0 None
2009-10-27 Positive results from Phase II clinical trial of INT-747 announced 0 None
2009-10-27 Positive results from Logical Therapeutics' Phase I/II LT-NS001 clinical study 0 None
2009-10-27 PolyMedix completes second successful clinical study of PMX-60056 0 5
2009-10-27 Lexicon Pharmaceuticals reports fiscal 2009 third-quarter results and updates of its clinical trials 0 None
2009-10-27 Phase 2 clinical study of PEG-Interferon lambda commenced 0 None
2009-10-27 LX211 may become the first approved oral treatment for modifying the course of uveitis 0 None
2009-10-27 Phase 3 trial results of Horizon Therapeutics's HZT-501 presented at the ACG meeting 0 None
2009-10-27 New data from efficacy study of CIMZIA in Crohn's disease patients presented 0 None
2009-10-27 Impax Pharmaceuticals begins Phase III trial of IPX066 drug in PD patients 0 None
2009-10-27 New data demonstrates CREON Delayed-Release Capsules improve fat absorption in adults with EPI 0 None
2009-10-27 Clinical trial helps improve prognosis and changes the standard of care for patients with colorectal cancer 0 None
2009-10-26 Analysis from Phase 3 trials of HZT-501 presented at 74th ACG meeting 0 None
2009-10-26 ImmunoCellular Therapeutics to present Phase I clinical trial data of ICT-107 vaccine in New Orleans 0 None
2009-10-26 Phase 2a clinical trial in nonsense mutation hemophilia A and hemophilia B initiated 0 None
2009-10-26 Results from Phase I dose-escalation study of AT-101 announced 0 3
2009-10-26 Cel Sci completes its production facility for Multikine Phase III clinical trial 0 None
2009-10-26 UCSF presents update of Phase 2 clinical trial of Oncophage cancer vaccine at SNO 2009 0 None
2009-10-26 Santarus to present results from two investigator-initiated studies with ZEGERID at 2009 ACG meeting 0 None
2009-10-26 Dexmedetomidine can reduce pain when removing a tube from the airway of critically ill patients 0 None
2009-10-26 Orexigen Therapeutics announces new data from COR-I, COR-II and COR-Diabetes trials for Contrave 0 5
2009-10-24 CHMP grants positive opinion to extend the use of Angiox to patients undergoing PCI 0 None
2009-10-24 Updated data on XL184 study in patients with glioblastoma multiforme presented 0 3
2009-10-24 TransMolecular announces final results from its Phase 2 clinical study of 131I-TM601 0 None
2009-10-23 Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals start Phase 3 trial to evaluate Nexavar tablets 0 None
2009-10-23 In vitro activity results of Cem-101 against gram-positive organisms to be presented 0 None
2009-10-23 TargeGen completes JAK2 inhibitor TG101348 clinical trial in myelofibrosis patients 0 None
2009-10-23 Affymax to make multiple presentations on preclinical and clinical data of Hematide 0 5
2009-10-23 Positive results from Phase 2 clinical trial of ARX-03 announced 0 None
2009-10-22 KemPharm commences KP106 Phase 1 clinical trial for ADHD 0 None
2009-10-22 Positive results from Aerie Pharmaceuticals’ Phase 2a study of its Rho-kinase inhibitor 0 None
2009-10-22 PacificGMP selected by ArmaGen Technologies to produce its proprietary protein for a Phase 1 clinical trial 0 None
2009-10-22 Pharmos announces results of its Phase 2b Dextofisopam trial 0 None
2009-10-22 Highlights of Cell Therapeutics' pixantrone study to be presented at the Lymphoma and Myeloma Conference 0 5
2009-10-22 Sosei Group announces Phase III trials update on NVA237 and QVA149 0 None
2009-10-22 ISTA Pharmaceuticals' presentations on Phase 3 clinical results of Bepreve 0 None
2009-10-22 Dose optimization data from Tolerx's Phase 2 clinical study of otelixizumab 0 None
2009-10-22 Peregrine Pharmaceuticals reports positive results from Phase II trial of bavituximab 0 None
2009-10-22 Halozyme Therapeutics commences patient dosing in Phase 3 Enhanze trial with Herceptin 0 None
2009-10-22 Study compares effects of clin-BPO 2.5% and clin-BPO 5% on epidermal functions 0 None
2009-10-22 New findings from ADVANCE clinical trial presented 0 None
2009-10-22 Millennium commences Vc-R-CHOP Phase II trial for diffuse large B-cell lymphoma 0 None
2009-10-22 Positive results from Isis Pharmaceuticals' ISIS 113715 Phase 2 study in type 2 diabetes patients 0 None
2009-10-21 Positive results from Argos Therapeutics' personalized immunotherapy candidate AGS-004 Phase 2a trial 0 None
2009-10-21 Northwest Biotherapeutics announces long-term data from Phase I and Phase I/II clinical trials of DCVax-Brain 0 4.5
2009-10-21 CombinatoRx announces Synavive Phase 2 extension trial results at the 2009 ACR meeting 0 None
2009-10-21 Celsion completes patient enrollment in its global Phase III ThermoDox trial 0 None
2009-10-21 Delcath Systems completes its pivotal Phase III Metastatic Melanoma Trial enrollment 0 None
2009-10-21 New results from ADVANCE provide important insights to reduce diabetes complications 0 5
2009-10-21 Clinical data supports continued development of ORENCIA administration for rheumatoid arthritis 0 None
2009-10-21 Genzyme commences patient enrollment in Genz-112638 phase 3 trials 0 None
2009-10-21 MediWound reports positive results from phase III Debrase trial for treating burns 0 None
2009-10-21 AFFiRiS reports encouraging results from clinical studies of its two Alzheimer's vaccines 0 None
2009-10-20 Positive results from KAI Pharmaceuticals' pain therapeutic program 0 None
2009-10-20 Tarsa Therapeutics receives license for Phase III oral calcitonin program 0 None
2009-10-20 Positive data from BioSante Pharmaceuticals' LibiGel Phase III clinical development program 0 None
2009-10-20 Targacept presents data from Phase 2b clinical trial of TC-5214 0 None
2009-10-20 Novartis' Tasigna capsules meets primary endpoint in comparison trial with Gleevec 0 None
2009-10-20 Bristol-Myers Squibb presents study data on ORENCIA for treating rheumatoid arthritis 0 None
2009-10-20 Repligen completes patient treatment in its Phase 3 RG1068 clinical trial 0 None
2009-10-20 SIMPONI treatment results in greater inhibition of structural damage in arthritis patients 0 None
2009-10-20 Elan and Biogen Idec to present TYSABRI study data at ACG meeting 0 None
2009-10-20 Trial collaborators present results from Prime-Boost HIV Vaccine Clinical Trial 0 None
2009-10-20 AstraZeneca and POZEN announce the pivotal data from two POZEN clinical trials 0 None
2009-10-20 Cumberland Pharmaceuticals publishes data on its Phase III intravenous ibuprofen study 0 None
2009-10-20 NicOx presents data on its phase 3 naproxcinod study at the ACR meeting 0 None
2009-10-20 Rexahn Pharmaceuticals announces positive results from Phase IIa Serdaxin clinical study 0 None
2009-10-20 Optimer Pharmaceuticals to present additional data on fidaxomicin at the 47th IDSA meeting 0 5
2009-10-20 Human Genome Sciences and GlaxoSmithKline to present Phase 3 trial results of BENLYSTA 0 None
2009-10-20 Celgene Corporation updates on Phase II study evaluating apremilast in psoriatic arthritis patients 0 None
2009-10-20 Jennerex' JX-594 granted European Orphan Drug Designation for the treatment of hepatocellular carcinoma 0 None
2009-10-20 Interim results from Phase 1 CAL-101 trial for chronic lymphocytic leukemia 0 None
2009-10-20 Positive results from Transave's Phase II ARIKACE clinical trials 0 None
2009-10-19 UCB reports on the outcome of Cimzia and MTX treatment for rheumatoid arthritis 0 None
2009-10-19 Alnara Pharmaceuticals’ announces results of its international Phase 3 study of liprotamase 0 None
2009-10-19 Philippines and Malaysian regulatory agencies approve Celsion’s Phase III Thermodox trial 0 None
2009-10-19 Amarin selects Medpace as CRO for its Phase 3 AMR101 MARINE clinical study 0 None
2009-10-19 New data on Phase 3 SIMPONI clinical trials for rheumatoid arthritis 0 None
2009-10-19 Positive results from Trubion Pharmaceuticals' Phase 2B study of TRU-015 for rheumatoid arthritis 0 None
2009-10-19 Schering-Plough to present data on boceprevir at the AASLD 2009 Annual Meeting 0 None
2009-10-19 Ardea Biosciences reports results of RDEA594 Phase 2a study for hyperuricemia and gout 0 None
2009-10-19 Phase 3 clinical trial of macimorelin (AEZS-130) to be completed by AEterna Zentaris 0 None
2009-10-19 XenoPort commences Phase 2b arbaclofen placarbil clinical trial for treating gastroesophageal reflux disease 0 None
2009-10-19 Antisense Pharma's SAPPHIRE Phase III trial evaluating trabedersen approved by Health Canada 0 None
2009-10-19 Genentech reports results of ACTEMRA Phase III study for rheumatoid arthritis 0 None
2009-10-19 Angiochem reports Phase 1/2 efficacy study results of ANG1005 for treating brain cancer 0 None
2009-10-19 NanoBio's NB-401 preclinical data to be presented at the 2009 North American Cystic Fibrosis Conference 0 None
2009-10-19 Angiochem announces results of Phase 1 /2 clinical trials of ANG1005 0 None
2009-10-19 Cardium Therapeutics reports positive findings from Excellarate Phase 1/2 clinical study 0 None
2009-10-19 Phase I clinical study of PENNVAX-B preventive DNA vaccine using electroporation technology 0 None
2009-10-19 FDA grants marketing approval for Elitek 0 None
2009-10-15 China's SFDA approves Celsion’s global Phase III ThermoDox HEAT trial for treating liver cancer 0 3
2009-10-15 Soligenix commences enrollment in its Phase 3 Orbec clinical trial for acute GI GVHD 0 None
2009-10-15 Inspire to present its denufosol tetrasodium cystic fibrosis program data at the 23rd NACFC 0 None
2009-10-15 Positive results from Protalix BioTherapeutics Phase III UPLYSO clinical trial 0 None
2009-10-15 pSivida achieves milestone in Phase III Iluvien trial, last patient completes two-year follow up visit 0 None
2009-10-15 Cytheris initiates Phase I/IIa dose escalation study of patients suffering from ICL 0 None
2009-10-15 Jazz Pharmaceuticals to present Phase III sodium oxybate trial data at ACR 2009 meetings 0 None
2009-10-15 Positive data from Cardium Therapeutics' Matrix Phase 2b Excellarate trial 0 None
2009-10-14 FDA approves ZyStor Therapeutics' ZC-701 for Phase I human safety trial 0 None
2009-10-14 Positive data from ZIOPHARM's palifosfamide sarcoma Phase II trial 0 None
2009-10-14 EMEA grants ArQule's ARQ 197 orphan drug designation 0 None
2009-10-14 Provectus Pharmaceuticals commences compassionate use program of PV-10 for cancer 0 None
2009-10-14 Nobilon initiates a clinical Proof of Concept trial with SCH 900795 vaccine 0 None
2009-10-14 Galapagos extends collaboration with Merck to develop new therapies for atherosclerosis 0 None
2009-10-14 Positive results from Metabolex' Phase 1 MBX-2982 clinical trial for treating type 2 diabetes 0 None
2009-10-14 AVANIR Pharmaceuticals announces results of Zenvia double-blind Phase III STAR trial 0 None
2009-10-13 Positive results from Alkermes' ALKS 33 clinical trials announced 0 None
2009-10-13 Sanofi-aventis collaborates with Merrimack Pharmaceuticals for rights to human monoclonal antibody MM-121 0 None
2009-10-13 Sequella receives Phase 1 SBIR grant for developing SQ641 0 None
2009-10-13 Provectus Pharmaceuticals completes initial treatment in Phase 2 trial of PH-10 for plaque psoriasis 0 None
2009-10-12 Arena Pharmaceuticals to present Phase 3 BLOSSOM trial results at Obesity 2009 0 None
2009-10-12 Synta Pharmaceuticals updates its Phase 3 SYMMETRY trial results at the Melanoma XIII Conference 0 None
2009-10-12 Celator Pharmaceuticals enrolls 120 patients in CPX-351 Phase 2 study 0 None
2009-10-12 Depomed announces results from BREEZE 1 and 2 Phase 3 clinical trials of Serada 0 None
2009-10-12 NOXXON Pharma announces the successful completion of the first phase I trial of Spiegelmer NOX-E36 0 None
2009-10-12 Results of Phase 2a clinical trial of DR Cysteamine announced by Raptor Pharmaceutical 0 None
2009-10-12 Nektar Therapeutics presents the results from Phase 2 clinical trial of oral NKTR-118 0 None
2009-10-12 NIH to launch 2009 H1N1 influenza vaccine trials in HIV-infected pregnant women, children and youth 0 None
2009-10-12 Phase I clinical trial results for Fentanyl Lauriad announced by BioAlliance Pharma 0 None
2009-10-12 NIH launches trial for the determination of 2009 H1N1 influenza vaccine for asthma patients 1 None
2009-10-11 World’s first engineered T cell receptor trial opens with new cellular therapy for HIV 0 None
2009-10-09 Riley Hospital for Children commences patient enrollment in clinical trial of cystic fibrosis drug 0 None
2009-10-09 Additional Zenvia Phase III results in multiple sclerosis announced by AVANIR 0 None
2009-10-09 Plexxikon commences patient dosing in PLX3397 Phase 1 clinical trial 0 None
2009-10-08 Lpath reports positive Phase 1 clinical trial results of iSONEP in wet-AMD patients 0 None
2009-10-08 Keryx Biopharmaceuticals commences Phase 2 clinical study evaluating KRX-0401 for Chronic Lymphocytic Leukemia 0 None
2009-10-08 Paratek Pharmaceuticals and Novartis to collaborate in PTK 0796 broad-spectrum antibiotic development 0 None
2009-10-08 Macuclear and Mystic announce groundbreaking results from Phase Ib Clinical Trial for Macular Degeneration 0 None
2009-10-07 Relypsa commences patient enrollment in Phase 2b clinical trial of RLY5016 for treating hyperkalemia 0 None
2009-10-07 Cipher Pharmaceuticals enrolls first patient in Phase III study of CIP-ISOTRETINOIN 0 None
2009-10-07 Zelos Therapeutics commences patient dosing of ZT-034 for treating osteoporosis 0 None
2009-10-07 Idera Pharmaceuticals commences phase 1 IMO-2125 clinical trial for chronic HCV infection 0 None
2009-10-07 Pharmaceutical companies gearing up for cancer vaccine trials following FDA draft guidance 0 None
2009-10-07 Merz publishes Phase III study results assessing the impact of NT 201 on muscle tone 0 None
2009-10-07 Biovail provides update on its Phase III program with pimavanserin for Parkinson’s disease psychosis 0 None
2009-10-07 Early Phase II clinical trial for RK-023 to treat androgenetic alopecia 0 None
2009-10-06 Phase 2 clinical study results of TOPICA's luliconazole for athlete's foot announced 0 None
2009-10-06 US Army grants BioDelivery Sciences $1.3M for investigating Bioral Amphotericin B 0 None
2009-10-06 AVANIR's STAR trial Phase III data to be presented at the World Congress on Controversies in Neurology 0 None
2009-10-06 Phase 3 results of Transdel's lead topical pain drug Ketotransdel announced 0 None
2009-10-06 Vantia Therapeutics announces the start of Phase II proof-of-concept trials of its VA111913 drug 0 None
2009-10-06 PDS Biotechnology's Versamune-based immunotherapy drug demonstrates safety in preclinical studies 0 None
2009-10-06 OncoGenex' OGX-011 receives additional FDA Fast Track Designation for treating metastatic prostate cancer 0 5
2009-10-06 EP-100 membrane-disrupting peptide drug for cancer being tested at TCRS 0 5
2009-10-06 ThromboGenics presents Phase IIa microplasmin intravitreal injection trial results at the ASRS conference 0 None
2009-10-05 ArQule completes patient enrollment in ARQ 197 Phase 2 trial for non-small cell lung cancer 0 None
2009-10-05 Alnara to announce Phase 3 study results of liprotamase for treating cystic fibrosis at the 23rd NACFC 0 None
2009-10-05 VIVUS to present data on Qnexa at The Obesity Society meeting 0 None
2009-10-05 Phase 3 clinical study results of Ketotransdel topical cream to be presented 0 None
2009-10-05 Preclinical study results of AVL-181 protease inhibitor presented 0 5
2009-10-05 Positive results from Peregrine's Phase II bavituximab trial for non-small cell lung cancer 0 5
2009-10-05 Cumberland to present clinical trial data of Caldolor at the AAPM annual meeting 0 None
2009-10-05 Prednisporin is a key asset in the proposed acquisition of Fovea by Sanofi-Aventis 0 None
2009-10-05 Seattle Genetics discontinues its SeaGen MARINER clinical trial for large B-cell lymphoma 0 None
2009-10-05 Positive results from Depomed's Phase 3 clinical trial of DM-1796 for postherpetic neuralgia 0 None
2009-10-05 GSK reports positive Phase II results from trial evaluating GSK1838262 for post-herpetic neuralgia 0 None
2009-10-05 Phase I clinical trial results to test the safety and immunogenicity of VGX-3100 released 0 None
2009-10-05 Genentech announces two Phase III study results of Lucentis 0 5
2009-10-03 Xcellerex and Itero collaborate in production of an undisclosed therapeutic protein 0 None
2009-10-03 Bristol-Myers Squibb to present new data on BARACLUDE and other compounds at the AASLD 2009 0 None
2009-10-03 Cardium announces positive results from the Phase 1 / 2 clinical study of Excellarate 0 None
2009-10-03 Clinical study data of Thymosin beta 4 presented 0 None
2009-10-03 Avexa's ATC Phase III study concludes 0 None
2009-10-03 Interim results of Sanofi Pasteur's Influenza A (H1N1) 2009 Monovalent Vaccine clinical trials announced 0 None
2009-10-03 KYTHERA Biopharmaceuticals presents its two Phase 2 clinical study results 0 None
2009-10-03 Phase 1b clinical trial results of PEG-Interferon lambda to be presented 0 5
2009-10-03 Telik's announces positive results from Phase 1-2a TELCYTA-carboplatin-paclitaxel combination study 0 None
2009-10-03 Dapagliflozin with metformin reduces glycosylated hemoglobin level and body weight 1 None
2009-10-03 NIH awards Titan $7.6M grant for Probuphine clinical development 0 None
2009-10-02 Preliminary Phase 2 study results of Plicera drug released 0 None
2009-10-01 Orexigen's Empatic Phase 2b results demonstrate weight loss 0 None
2009-10-01 Catalyst Pharmaceutical Partners to continue development of CPP-109 drug 0 None
2009-10-01 Phase 2 study of PH20 with regular human insulin confirms faster insulin absorption 0 None
2009-10-01 Merrimack and sanofi-aventis collaborate to develop and co-commercialize MM-121, a monoclonal antibody 0 None
2009-10-01 Provectus Pharmaceuticals commences Phase 1 study of PV-10 for liver cancer 0 None
2009-10-01 Phase 1 clinical trial to test safety and activity of human MAB launched in India 0 None
2009-10-01 Promising results from Cell Therapeutics' phase II OPAXIO study for advanced esophageal cancer 0 None
2009-10-01 Imthera Medical receives Ethics Committee clearance to start human clinical trials in Belgium 0 None
2009-10-01 Resverlogix RVX-208 exceeds expectations in Phase 1b/2a clinical trial 0 None
2009-10-01 Ardea's to present its hyperuricemia canditate study results at the ACR/ARHP Scientific Meeting 0 None
2009-10-01 Update from BioCryst Pharmaceuticals regarding intravenous peramivir 0 None
2009-10-01 Can-Fite BioPharma commences preparatory work for a Phase III trial with CF101 to treat Psoriasis 0 None
2009-10-01 Welichem announces filing of clinical trial application with Health Canada 0 None
2009-09-30 MacuSight's clinical development update on its proprietary ocular sirolimus product 0 None
2009-09-30 Amicus Therapeutics to initiate Phase 1 study of AT2220 0 None
2009-09-30 Phase III clinical trial results demonstrate effectiveness of spinosad suspension 0 None
2009-09-30 Æterna Zentaris announces results of its cetrorelix pamoate clinical development program TQT trial 0 None
2009-09-30 Polymedix commences Phase 1B study of novel anticoagulant reversing agent 0 None
2009-09-30 Plexxikon commences patient dosage in PLX4032 trials for metastatic melanoma 0 3.7
2009-09-30 Results from Phase 2 clinical study of LCP-Tacro tablets in stable liver transplant patients announced 0 4
2009-09-30 AFRESA Inhalation Powder and AFRESA Inhaler NDA under FDA review 0 None
2009-09-29 Vitae receives 11Beta-HSD-1 program milestone payment from Boehringer Ingelheim 0 None
2009-09-29 NIH awards Novelos and MGH $1M grant for the study of compounds for radiation-induced lung injury 0 None
2009-09-29 pSivida reports interim results of human PK study of Iluvien 0 None
2009-09-29 Synta commences Phase 1/2 clinical study of novel Hsp90 inhibitor in hematologic malignancies 0 None
2009-09-29 Acrux reports Phase III trial results evaluating AXIRON for testosterone deficiency 0 5
2009-09-29 Dynavax commences Phase 3 trial for HEPLISAV hepatitis B vaccine 0 None
2009-09-29 International Medica Foundation sponsors rotavirus vaccine trial in Ghana 0 None
2009-09-28 Kane Biotech's Dispersinb Topical Wound Gel passes cytotoxicity and primary skin irritation tests 0 5
2009-09-28 NIH awards DiscoveryBioMed a Phase 2 SBIR grant for research on hypertension and cystic fibrosis 0 None
2009-09-28 Halozyme Therapeutics announces Phase 1 clinical study to assess three insulin analogs 0 None
2009-09-28 Phase 2 clinical trial results of IMO-2055 announced 0 None
2009-09-27 Investigational vaccine regimen 31% effective in preventing HIV infection 0 None
2009-09-26 Pfizer to commence Phase 3 trial of oral c-Met and ALK inhibitor 0 1
2009-09-26 Morphotek announces preliminary data from Phase II trial of farletuzumab 0 None
2009-09-25 Dyax to present an update of its clinical development programs 0 None
2009-09-25 NCI awards Altor Bioscience a $3 MM grant to develop its targeted cancer therapeutic ALT-801 0 None
2009-09-25 US Treasury Department clears YM BioSciences' nimotuzumab clinical program extension 0 None
2009-09-25 Phase III PLATO study proves that ticagrelor is more effective than clopidogrel 0 3
2009-09-25 Results from COGENT clinical trial presented at TCT symposium 0 None
2009-09-25 Huachansu may slow cancer progression 0 None
2009-09-25 Partial success reported in the Phase 3 trial of HIV/AIDS vaccine 0 None
2009-09-24 CTRC commences patient enrolment in Phase 2 clinical trial of REOLYSIN for metastatic melanoma 0 None
2009-09-24 Karo Bio announces clinical phase II results of thyroid hormone analog eprotirome 0 None
2009-09-24 Phase II study of OPAXIO to be revealed 0 None
2009-09-24 Phase III efficacy trial of two AIDS vaccine candidates shows promise 0 5
2009-09-24 ThromboGenics completes enrollment for MIVI-TRUST clinical trial 0 None
2009-09-24 CEL-SCI Corporation engages a CRO for clinical trial of its investigational LEAPS-H1N1 treatment 0 None
2009-09-24 MicroDose initiates Phase 1 clinical trial investigating the pharmacokinetics of atropine inhalation 0 None
2009-09-24 Enrollment for pSivida's pilot FAVOR clinical study commences 0 None
2009-09-24 FDA endorses Covidien's REMS program for EXALGO tablets 1 None
2009-09-24 Results of Phase III clinical trial of HIV vaccine released 0 None
2009-09-24 Medivation commences patient treatment in clinical trial of MDV3100 in advanced prostate cancer 1 5
2009-09-24 Lux Biosciences announces results of its LX214 human safety study for dry eye syndrome 0 None
2009-09-23 Oxygen Biotherapeutics to commence Phase II-b trial of Oxycyte in treating traumatic brain injury 0 None
2009-09-23 Results of Phase 3 CRYSTAL study of mCRC patients announced 0 5
2009-09-23 FDA accepts Sangamo's IND for repeat-dosing in Phase 1 clinical trial of SB-728-T ZFN-based therapeutic 0 4
2009-09-23 Pluristem commences dosing in Phase I clinical trial for the treatment of critical limb ischemia 0 None
2009-09-23 Phase 2 trial results of Bayer's Nexavar in combination with capecitabine announced 0 None
2009-09-23 Phase 1b interim clinical trial results of IMO-2055, Tarceva and Avast combination announced 0 None
2009-09-23 Phase 1 extension study results of Plexxikon's PLX4032 in metastatic melanoma patients encouraging 0 5
2009-09-23 Drug trial for OSI-906 begins 0 None
2009-09-23 CERE-110 trial to stop the progression of Alzheimer's disease 0 None
2009-09-23 BioMarin commences PEG-PAL Phase 2 clinical trial for phenylketonuria 0 5
2009-09-22 Amgen announces results of Phase 3 head-to-head trial evaluating denosumab versus Zometa 0 None
2009-09-22 NicOx announces publication of blood pressure results from the phase 3 study of naproxcinod 0 None
2009-09-22 Researchers to present results of HORIZONS-AMI trial at TCT scientific symposium 0 None
2009-09-22 IRSF announces funding of new clinical study with disease-modifying therapy treatment for Rett syndrome 0 None
2009-09-22 Amgen announces Phase 3 results evaluating Vectibix in combination with FOLFIRI chemotherapy 0 None
2009-09-22 Bayer's regorafenib showed 50% stabilization rate in RCC patients 0 None
2009-09-22 Interim data from Micromet's T-cell engaging BiTE antibody study for treating solid tumors 0 None
2009-09-21 Vitae Pharmaceuticals initiates Phase 1 clinical trial of its novel cardiovascular agent 0 None
2009-09-21 Provectus' Phase 2 clinical trial of PV-10 for metastatic melanoma complete 0 5
2009-09-21 Enzo Biochem and NEI join to conduct a human clinical trial of Enzo’s chronic autoimmune uveitis therapeutic 0 None
2009-09-21 Clinical trial results of topical INCB18424 inhibitor announced by Incyte Corporation 0 None
2009-09-21 Anavex completes manufacturing of Alzheimer's disease drug ANAVEX 2-73 for its clinical trials 0 None
2009-09-21 Perrigo purchases KV Pharmaceutical's ANDA for clindamycin phosphate and benzoyl peroxide gel 0 None
2009-09-21 Celsion recommended to continue patient enrollment in its ThermoDox Phase III liver cancer trial 0 None
2009-09-21 Phase II trial of Impax Pharmaceuticals' Parkinson’s disease drug candidate successful 0 None
2009-09-21 FDA approves Neuralstem's IND for commencing a stem cell trial to treat Amyotrophic Lateral Sclerosis 0 3
2009-09-21 Phase 1 clinical trial results evaluating ARIAD's investigational mTOR inhibitor ridaforolimus 0 1
2009-09-21 Study reveals that patients with NSCLC who received maintenance therapy with ALIMTA showed survival benefit 0 None
2009-09-21 PROLOR Biotech initiates Phase I clinical trial of its human growth hormone drug candidate 0 None
2009-09-21 Results of Phase 1 study of Oral AEZS-112 announced by Aeterna Zentaris 0 None
2009-09-21 NIAID awards Antigen Discovery a Phase II STTR grant for Chlamydia vaccine development 0 5
2009-09-21 Amgen announces results of Phase 3 trial in the treatment of bone metastases 0 None
2009-09-19 Millennium's sNDA for VELCADE granted priority review by the FDA 0 None
2009-09-18 Results from the BLOSSOM trial announced by Arena Pharmaceuticals 0 None
2009-09-18 Eastern Europe, Latin America and Asia are new regions for clinical trials 0 None
2009-09-17 Lantheus commences Phase 1 study evaluating novel LMI1195 heart failure imaging agent 0 None
2009-09-17 China SFDA approves clinical trial of China Aoxing's abuse resistant opioid drug 0 None
2009-09-17 Intarcia's ITCA 650 phase 2 study in type 2 diabetes begins patient enrollment 0 1
2009-09-17 Results from Phase IIb clinical trial evaluating the safety and efficacy of GSK1838262/XP13512 announced 0 None
2009-09-17 Bayer HealthCare to present its clinical trial data at a joint Multidisciplinary Congress 0 None
2009-09-17 Charley's Fund and the Nash Avery Foundation to support investigation of Galapagos' SARM candidate drug 0 None
2009-09-17 Genentech releases Phase III PRIMA study findings 0 None
2009-09-17 Bioheart's MARVEL Phase II/III clinical trial successful 0 None
2009-09-17 ULURU reports Altrazeal clinical trial results 0 None
2009-09-16 VOICE clinical study for testing the efficacy of two HIV prevention strategies 0 None
2009-09-16 Amgen to present its four Phase 3 clinical trial results 0 None
2009-09-16 FDA provides Orphan-Drug designation for Keryx' KRX-0401 to treat multiple myeloma 0 None
2009-09-16 CEL-SCI to commence its LEAPS-H1N1 clinical trial following FDA approval 0 5
2009-09-16 Celsion's DIGNITY clinical trial aired on Good Morning America 0 None
2009-09-16 Medivir presented preclinical data from its cathepsin K inhibitor program at the ASBMR meeting 0 None
2009-09-16 Savient updates on its Biologics License Application with the FDA for KRYSTEXXA 0 None
2009-09-16 Pros and cons of HIV treatments in developing countries 0 None
2009-09-16 Optimer's North American phase 3 Fidaxomicin study results presented at the 49th ICAAC 0 5
2009-09-16 Phase III EXTEND trial results of pixantrone announced 0 None
2009-09-16 Novartis presents Phase II results of the QVA149 bronchodilator for the treatment of COPD 0 None
2009-09-16 NIMH awards Genomas an SBIR Grant to develop MRI DNA biomarkers for neuropsychiatric disease 0 None
2009-09-16 NIAID awards Sanaria an SBIR Grant for expediting its malaria vaccine manufacturing process 0 None
2009-09-15 FDA approves BioVex' design of a Phase III clinical trial to evaluate OncoVEX 0 None
2009-09-15 Alvine Pharmaceuticals raises funds for Phase 2a clinical trial of its lead compound ALV003 0 None
2009-09-15 Hyperion enrolls first patient in HPN-100 investigational compound clinical trial 0 None
2009-09-15 Palatin Technologies to announce clinical trial results of PL-3994 0 None
2009-09-15 Extension study data on Fampridine-SR drug 0 None
2009-09-15 Alnylam and Medtronic announce pre-clinical research findings from their Huntington’s disease program 0 None
2009-09-15 Lexicon initiates Phase 2 clinical trial of LX4211 in patients with type 2 diabetes mellitus 0 None
2009-09-15 KYTHERA initiates proof-of-concept trial of its ATX-104 light-activated facial contouring agent 0 None
2009-09-15 Cytheris' INSPIRE study data of HIV-infected patients with low CD4 T cell counts announced 0 None
2009-09-15 Phase III results of Lauriad presented at the 49th Annual ICAAC 0 None
2009-09-15 Phase II VICTOR-E1 clinical study results reported 0 None
2009-09-15 NanoBio presents preclinical data of NB-201 for treating burn wounds at the 2009 ICAAC 0 None
2009-09-15 Phase II clinical study results of Kamada's inhaled-AAT for cystic fibrosis presented at the ERS Congress 0 None
2009-09-15 NovaBay's Aganocide compounds effective against multidrug-resistant bacteria 0 None
2009-09-15 Rib-X and NIAID collaborate to develop an antibiotic treatment for N. gonorrhoeae 0 None
2009-09-15 Positive results from Merck's Phase IIB clinical study of odanacatib for treating osteoporosis 0 None
2009-09-15 Phase 2b trial of Mpex's Aeroquin with PARI Pharma's eFlow Nebulizer System successful 0 None
2009-09-15 Phase I results of Tobira's TBR-652 CCR5 antagonist for the treatment of HIV 0 None
2009-09-15 FDA provides a complete response letter for Digestive Care's PANCRECARB 0 None
2009-09-14 BioAlliance announces Phase III results of miconazole Lauriad MBT for treatment of oropharyngeal candidiasis 0 None
2009-09-14 Biotie Therapies commences clinical trial with its phosphodiesterase 4 inhibitor ELB353 0 5
2009-09-14 Phase 1 trial results of Achaogen's ACHN-490 announced at ICAAC meeting 0 None
2009-09-14 Phase 2b clinical trial results of Dextofisopam to treat irritable bowel syndrome announced 0 None
2009-09-14 Clinical studies reveal treatment with pirfenidone is safe and well-tolerated 0 None
2009-09-14 Results from Keryx' KRX-0401 Phase 2 study to be presented at the International Kidney Cancer Symposium 0 None
2009-09-14 Cytrx initiates tamibarotene and TRISENOX combination dose escalation study 0 None
2009-09-14 Celldex commences dosing patients in Phase 1/2 study of its CDX-1401 vaccine candidate 0 None
2009-09-14 Altair announces positive Phase I results for AIR645 in treating asthma 0 None
2009-09-14 Zabecor Pharmaceuticals initiates Phase II clinical trial of its Excellair asthma drug 0 None
2009-09-14 Positive results from Transave's Phase II clinical trial of ARIKACE in non-CF bronchiectasis patients 0 None
2009-09-14 Enobia Pharma's clinical study of ENB-0040 for treating hypophosphatasia provides positive results 0 None
2009-09-14 Protalix Biotherapeutics reports completion of its Phase III trial of prGCD 0 None
2009-09-14 Phase 1 results of CTP-347 presented 0 None
2009-09-14 Preliminary results of Phase 2b clinical trial of AZ-104 announced by Alexza Pharmaceuticals 0 None
2009-09-14 ARIAD to complete its Phase 3 SUCCEED trial following DMS recommendation 0 None
2009-09-14 Data from Phase 1 and Phase 2a studies of inhaled liposomal ciprofloxacin to be presented at ERS Congress 0 None
2009-09-14 Final results of SAPHRIS clinical study released 0 None
2009-09-14 Patient enrollment for Phase 3 clinical trials of VEGF Trap-Eye completed 0 None
2009-09-14 GTx to continue its toremifene Phase III high grade PIN clinical trial for prevention of prostate cancer 0 5
2009-09-14 Phase 3 results of TARGET 1 and TARGET 2 clinical trials released 0 None
2009-09-14 Phase IIa clinical data of EHT 0202 released 0 None
2009-09-14 Phase III STARTMRK clinical study on ISENTRESS in comparison to efavirenz 0 1
2009-09-14 Clinical data on CXA-101 to be presented at ICAAC 0 None
2009-09-14 Tobira Therapeutics presents TBR-652 in vitro data for treating HIV at the 49th ICAAC 0 None
2009-09-14 Clinical data emphasizing on efficacy and potency of torezolid to be presented 0 None
2009-09-14 Phase III clinical trial results of DAR-31 published 0 None
2009-09-14 Data from Phase III clinical trial of TYSABRI presented at ECTRIMS 0 None
2009-09-14 Influenza patients treated with Tamiflu has higher survival rates 0 None
2009-09-14 Phase IIa trial results of panobacumab released 0 None
2009-09-14 FOCUS 1 and FOCUS 2 clinical trial results released 0 None
2009-09-14 NIAID conducts human clinical trials of 2009 H1N1 influenza vaccines 0 None
2009-09-14 Oral NKTR-118 has low risk for mediating significant drug-drug interactions 0 None
2009-09-14 Phase 2 MS clinical trial data continues to show durable reductions in relapse rate 0 None
2009-09-13 AVONEX results in fewer injection site reactions, according to a clinical study 0 None
2009-09-11 Genspera to commence G-202 Phase I trial following FDA approval 0 None
2009-09-11 Results from the BRITE-MD trials published in Psychiatry Research: Aspect Medical Systems 0 None
2009-09-11 Dyax' Phase 3 hereditary angioedema clinical program affirms reliability of its novel PROs 0 None
2009-09-11 Delcath Systems to continue Phase III clinical trial 0 None
2009-09-11 Pluristem begins enrollment following FDA approval for clinical trials of its PLX-PAD stem cell product 0 None
2009-09-11 First patient enrolled in Phase 2b RADAR clinical trial 0 None
2009-09-11 Phase 3 trial results of LEVADEX orally inhaled migraine therapy to be presented 0 None
2009-09-11 Update on Prolindac clinical development plan provided by Access Pharmaceuticals 0 None
2009-09-11 Merck update on the status of telcagepant clinical development programs 0 4
2009-09-11 Positive results from Mpex' Phase 2b clinical trial with Aeroquin 0 None
2009-09-10 Phase II human clinical trial of Exsulin commences 0 None
2009-09-10 Esperance Pharmaceuticals begins human clinical trials of its EP-100 cancer therapeutic candidate 0 5
2009-09-10 Teva's COPAXONE holds promise for relapsing remitting multiple sclerosis 0 4
2009-09-10 NIH provides Inviragen second major grant to develop a dengue vaccine 0 None
2009-09-10 Acceleron's Phase 1 trial of ACE-031 reveals its potential in treating neuromuscular diseases 0 5
2009-09-10 Human neural stem cells to treat Pelizaeus-Merzbacher Disease 0 None
2009-09-10 GI Company's Phase II study demonstrates safety of rhITF oral spray formulation 0 None
2009-09-10 FDA approves Ascenta's IND for AT-406 multi-IAP antagonist 0 None
2009-09-10 Phase III trial demonstrates rapid efficacy of Zelrix in treating acute migraine 0 None
2009-09-10 Quatrx' second phase 3 study of ospemifene tablets provides positive results 0 None
2009-09-10 Roche conducts third Phase 1 clinical trial utilizing Halozyme’s Enhanze Technology 0 None
2009-09-10 Protox' Phase 2 study of PRX302 for treating BPH provides positive results 0 None
2009-09-10 Acorda Therapeutics announces Phase 3 Fampridine-SR trial findings 0 1
2009-09-10 Affymax to complete Hematide Phase 3 clinical study by the end of 2009 0 None
2009-09-10 Cempra commences Phase 2/3 clinical study of CEM-102 for treating acute bacterial skin structure infections 0 None
2009-09-10 Galapagos starts new clinical trial for GLPG0259 0 None
2009-09-10 Patient enrollment completed in Phase 2b clinical trial for Pyridorin 0 None
2009-09-09 American Medical News examines clinical trials outsourcing 0 None
2009-09-09 Phase II trial of ANA598 commenced by Anadys Pharmaceuticals 0 None
2009-09-09 Protox Therapeutics to present TRIUMPH clinical study update 0 None
2009-09-09 VIVUS' Phase 3 studies find Qnexa effective in tackling obesity 0 5
2009-09-09 INSPIRE Phase I/IIa study data to be presented at ICAAC 0 None
2009-09-09 Synexus on track to double its clinical trial capacity in South Africa, opens two new research centres in Pretoria 0 None
2009-09-09 Patient enrollment completed in Phase II clinical trial of bavituximab 0 None
2009-09-09 Amarillo Biosciences is midway in Phase 2 clinical study of interferon against H1N1 0 None
2009-09-09 Preliminary Phase 3 clinical study results of T-Pred released 0 None
2009-09-09 Can-Fite's Phase II clinical study of CF101 provides positive results 0 None
2009-09-09 Phase 3 clinical trials of BHR-100 infusion to be initiated by BHR Pharma 0 None
2009-09-09 Study to test efficacy of lapatinib in advanced hepatocellular carcinoma 0 None
2009-09-09 Phase III trials for CS-8958 neuraminidase inhibitor successful 1 5
2009-09-08 Valeant develops an acne drug with a low concentration of BPO combined with clindamycin 0 None
2009-09-08 Preliminary results of Phase III Gvhd trials announced by Osiris Therapeutics 0 None
2009-09-08 Opexa Therapeutics releases Phase IIb TERMS clinical study results 0 None
2009-09-08 DOR's Phase 1/2 clinical trial for prevention of radiation enteritis receives NIH grant 0 None
2009-09-08 Patient enrollment for Phase 2b study of PRX302 completed by Protox Therapeutics 1 None
2009-09-08 Third human clinical trial of LigoCyte's norovirus vaccine started 0 4.8
2009-09-08 Recruitment for the Phase IIa clinical trial to assess CNS 7056 sedative completed by PAION 0 None
2009-09-05 Securities class action lawsuit filed against Repros Therapeutics 0 None
2009-09-04 Novel SLE Responder Index as the primary endpoint in two Phase 3 clinical trials 0 None
2009-09-04 Dilafor Phase II clinical trial completes 0 None
2009-09-04 OSI Pharmaceuticals initiates two clinical trials with OSI-906 oral insulin-like growth factor-1 receptor inhibitor 0 None
2009-09-04 Clinical trial of Novartis MF59 swine-flu vaccine elicits a strong immune response 0 5
2009-09-04 Two ongoing Phase 2 clinical trials of CPX-351 to be showcased 0 None
2009-09-04 Results of Phase 2 rheumatoid arthritis clinical trial announced 0 None
2009-09-03 Germany’s BMBF awards NOXXON grant for developing Spiegelmer NOX-A12 0 None
2009-09-03 Phase I clinical trial data of GDC-0449 published in the New England Journal Of Medicine 0 None
2009-09-03 Study reports a potential new investigational therapy for skin cancer 0 None
2009-09-03 First swine-flu vaccine trials reveal strong immune response 0 None
2009-09-03 CORD I phase III clinical trial results of XIAFLEX published 0 5
2009-09-03 New clinical trials to address the effectiveness of antimicrobial drugs 0 None
2009-09-03 Interim Phase II data of Cotara reveals signs of efficacy in GBM patients 0 None
2009-09-03 GDC-0449 inhibits the Hedgehog signaling pathway 0 4
2009-09-03 Avastin increases survival rates in recurrent glioblastoma affected patients 0 None
2009-09-02 Phase 1 single dose clinical trial of Acceleron Pharma's ACE-031 increases lean body mass 0 5
2009-09-02 FDA approves Astepro nasal spray 0.15% for the treatment of the symptoms of seasonal allergies 0 None
2009-09-02 Patents for treatment for obesity acquired by Madrona Ventures, to start clinical trials soon 0 4.2
2009-09-02 FDA: Randomized clinical trial necessary to better interpret Clolar’s efficacy and safety in adult AML 0 None
2009-09-02 Knopp Neurosciences to accelerate the development of KNS-760704 in ALS, says CEO of Knopp 0 None
2009-09-02 PROTECT clinical study aimed at the assessment of rolofylline effects 0 None
2009-09-02 Positive results from second pivotal phase III trial for Lodotra 0 None
2009-09-02 PLATO study reveals that ticagrelor reduces the rate of cardiovascular events 0 4.5
2009-09-02 High-density lipoprotein cholesterol concentrations increased in patients treated with LIVALO 0 4
2009-09-01 GS-101 effective in inhibiting and regressing corneal neovascularisation 0 None
2009-09-01 Cimzia approved for treating adult patients with rheumatoid arthritis 0 None
2009-09-01 TransPharma's Phase 2A trial of ViaDerm-hPTH(1-34) for treating severe osteoporosis is successful 0 1
2009-09-01 Results of the first pivotal Phase III trial with pimavanserin in patients with PDP announced 0 None
2009-09-01 Biovail announces Phase III trial results for pimavanserin 0 None
2009-09-01 Phase II result reveals effectiveness of GS-101 eye drops at inhibiting corneal neovascularisation 0 None
2009-09-01 Traditional lipid risk factors to be strong predictors of cardiovascular events according to a study 0 None
2009-08-31 Stanford University starts recruiting participants for swine flu vaccine clinical trial 0 None
2009-08-31 Clinical trial results of Dabigatran proves its effectiveness for treating atrial fibrillation 0 None
2009-08-31 Celladon announces completion of patient enrollment for Phase 2 CUPID clinical trial 0 None
2009-08-31 Sonomax Hearing Healthcare completes Phase II trials of a delivery mechanism that inflates a V3 earplug successfully 0 None
2009-08-31 BrainStorm Cell Therapeutics partners with Protein Production to start production of clinical-grade stem cell therapeutic product 0 None
2009-08-31 Cancer researcher to serve as Peregrine Pharmaceuticals' clinical advisor for bavituximab cancer program 0 None
2009-08-31 Results of the Phase II SEPIA-ACS1/ TIMI-42 study presented at the plenary session of the Annual European Society of Cardiology 0 None
2009-08-31 RE-LY trial establishes effectiveness of PRADAX in reducing stroke risk in AF patients 0 None
2009-08-30 Initial results of the CURRENT-OASIS 7 clinical trial due for release 0 None
2009-08-29 Global Markets Direct's new report on Spinal Fusion Clinical Trial Analysis 0 None
2009-08-29 Phase 2B clinical trial results of oral vernakalant to be presented at the ESC Congress 2009 0 None
2009-08-29 New report on product clinical trials conducted by Tissue Sealants manufacturers 0 None
2009-08-29 Global Markets Direct's new report pertains to product clinical trials being carried out by Repair and Restorative Materials manufacturers 0 None
2009-08-29 Two human biomarker assays that play a key role in the early detection of kidney damage provide assistance in drug development 0 None
2009-08-28 Facet Biotech And Trubion to jointly develop and commercialize the TRU-016 SMIP protein therapeutic 0 None
2009-08-28 Boston Scientific to discuss final results of MADIT-CRT trial at the European Society of Cardiology Congress 0 None
2009-08-28 Research And Markets' report on product clinical trials carried out by Spinal Non-Fusion manufacturers 0 None
2009-08-28 Polymedix And UMass receive Phase I STTR contract for research on drug-resistant bacteria treatments 0 None
2009-08-28 Forest Laboratories announces phase 3 trial results for roflumilast 0 2
2009-08-28 Forest Laboratories to host a conference call for discussing the results of Daxas Phase III clinical trials 0 None
2009-08-28 Infectious Disease Research Institute commences clinical trial of its leishmaniasis vaccine in Sudan 0 None
2009-08-28 Arno Therapeutics to commence Phase 1 clinical study of AR-12 in adult patients with lymphoma 0 None
2009-08-27 Lakewood-Amedex to speed up development of its broad spectrum anti-influenza product into clinical studies 0 None
2009-08-27 QRxPharma completes its pilot evaluation study investigating the efficacy of MoxDuo capsules 0 5
2009-08-27 Novelos Therapeutics enters into a definitive agreement with Purdue Pharma to raise funds 0 None
2009-08-27 BioAlliance Pharma's LIP phase III pivotal study provides positive preliminary results 0 None
2009-08-26 Quality test for Guardian Technologies International's Signature Mapping TBDx system completed 0 None
2009-08-26 New interactive web site launched by DATATRAK 0 None
2009-08-26 EPIX Pharmaceuticals' PRX-00023 Therapeutics CNS program in Phase 2B/3 offered for auction sale 0 None
2009-08-26 Morria Biopharmaceuticals receives approval to commence its Phase II clinical trial on MRX6 0 None
2009-08-26 Peptimmune's Phase Ib clinical trial of PI-2301 in multiple sclerosis patients complete 0 None
2009-08-26 Cardium announced that patients enrolled for MATRIX clinical trail have completed their evaluation period 0 None
2009-08-26 Patients enrolled in the TREAT Phase 3 study treated with Aranesp to a target hemoglobin of 13 g/dL 0 5
2009-08-26 Positive results obtained from phase 3 clinical trial of lurasidone for treating schizophrenia 0 None
2009-08-26 Phase III RE-LY study results to be presented at the European Society of Cardiology Congress 0 4
2009-08-26 Washington Post examines development of vaccine for food borne intestinal illness 0 None
2009-08-26 Alvine Pharmaceuticals commences Phase 2a clinical trial to evaluate the efficacy of ALV003 0 None
2009-08-25 Venlafaxine alleviates depressive symptoms 0 None
2009-08-25 Delcath Systems enrolls 85 patients for its pivotal Phase III Metastatic Melanoma Trial 0 None
2009-08-25 Subject enrollment in patients with retinitis pigmentosa for Phase 2 clinical study completed by R-Tech Ueno 0 None
2009-08-25 Seattle Genetics completes enrollment of its pivotal clinical trial of brentuximab vedotin 0 None
2009-08-25 Regado Biosciences to commence Phase I study of a subcutaneous administration formulation of the REG1 anticoagulation system 0 None
2009-08-25 Phase I/II trial of Amphinex uses photochemical internalisation approach 0 None
2009-08-24 Orphan drug status granted to BioCancell's BC-819 drug 0 None
2009-08-24 Retigabine's Phase IIa clinical trial preliminary results announced 0 None
2009-08-24 Israeli government and a private investment fund Brainstorm Cell Therapeutics to complete pre-clinical studies in ALS 0 None
2009-08-24 CSL Biotherapies initiates clinical trials of Influenza A/H1N1 2009 vaccine in the US 0 None
2009-08-24 Profibrix raises funds for clinical and preclinical development 0 None
2009-08-24 Biovail enters into an agreement with Santhera to develop and market JP-1730/fipamezole drug 0 None
2009-08-22 Adamas Pharmaceuticals forges agreement with U.S. Naval Health Research Center for evaluating triple combination antiviral drug 0 None
2009-08-21 Endologix publishes abdominal aortic aneurysm treatment trial results online 0 None
2009-08-21 NY-ESO-1 recombinant proteins to be used in clinical trials for treating melanoma and ovarian cancer 0 None
2009-08-20 Peplin completes four-week enrolment phase for REGION-Ib trial 0 None
2009-08-20 InterMune receives $20 million event payment from Roche for initiating the Phase 2b trial of RG7227/ ITMN-191 0 None
2009-08-19 Light Sciences Oncology announces Phase 2 trial of Aptocine in Benign Prostatic Hyperplasia 0 5
2009-08-19 Gentium reports results from phase 3 trial of defibrotide for severe veno-occlusive disease 0 None
2009-08-19 Sinovac Biotech announces positive results from clinical trial of H1N1 vaccine 0 None
2009-08-19 Arzoxifene phase 3 study results reported by Lilly 0 None
2009-08-19 Hard to Treat Diseases' swine flu clinical trials in progress 0 1
2009-08-19 Low-dose estrogen effective for metastatic breast cancer 0 None
2009-08-19 Results of Phase IIb dose range finding of oglemilast in chronic obstructive pulmonary disease announced 1 None
2009-08-19 Amarex joins OmniComm Systems' CRO Preferred Program 0 None
2009-08-18 4SC starts phase 2 trial in hepatocellular carcinoma with 4SC-201 (resminostat) 0 None
2009-08-18 Genentech announces Phase III study results for Avastin (bevacizumab) in combination with chemo in HER2-negative breast cancer 0 None
2009-08-17 Human Genome Sciences achieves systemic lupus goals with candidate drug 0 None
2009-08-17 Aeterna Zentaris announces results from trials of Cetrorelix in benign prostatic hyperplasia 0 None
2009-08-14 New immune therapy for kidney cancer tested 0 5
2009-08-13 First batch of cancer vaccine from Cancer Vaccine Collaborative goes into trial 1 None
2009-08-13 Antigenics’ Oncophage cancer vaccine trial starts enrolling patients 0 3
2009-08-12 Study looks at imipramine in the treatment of irritable bowel syndrome 0 5
2009-08-12 Cannabis Science reports on future plans for cannabis drug trials 0 None
2009-08-12 Investigational, orally-inhaled therapy effective in treating migraines 0 None
2009-08-12 Researchers respond to concerns about international insulin drug trial 0 None
2009-08-12 Endocyte announces results from study of EC145 in patients with advanced non-small cell lung cancer 0 None
2009-08-11 Britain's first swine flu vaccine trials start 0 None
2009-08-11 New type of anti-clotting drug called Apixaban 0 None
2009-08-11 Denosumab reduces fracture risk in men receiving androgen-deprivation therapy for prostate cancer 0 None
2009-08-11 Knopp Neurosciences to present phase 2 results of drug candidate in amyotrophic lateral sclerosis 1 None
2009-08-11 Gene Signal publishes phase I data on GS-101 for diseases of the eye 0 None
2009-08-11 Depomed reports promising results in phase I trial for DM-1992 in Parkinson’s 0 None
2009-08-11 Additional trial to be conducted for KYNAPID under FDA special protocol agreement 0 None
2009-08-10 Eiger Biopharmaceuticals starts CLEAN-1 HCV phase 1B trial 0 4
2009-08-10 Nanoviricides anti-herpes drug candidate reduces viral load by 99.99% 2 2
2009-08-09 Cost-effectiveness of Cetuximab in metastatic colorectal cancer 0 None
2009-08-06 Bellicum Pharmaceuticals starts phase I/II trial of novel advanced prostate cancer vaccine 0 None
2009-08-06 Phase 1 clinical trial starts for new antibody aimed at hepatitis C virus 0 None
2009-08-05 Baxter completes production of batches of CELVAPAN A/H1N1 pandemic vaccine 0 2
2009-08-04 Clinical trial to test gene therapy for Alzheimer’s disease 0 None
2009-08-04 Accelerating the development of new cancer drugs 0 None
2009-08-04 Women and minorities under-represented in trials 0 None
2009-08-03 Metformin associated with reduced risk of pancreatic cancer in diabetics 0 None
2009-08-02 Tarceva shown to extend survival in advanced non-small cell lung cancer when used after initial chemo 0 None
2009-07-31 Medicago announces positive results for H1N1 pandemic vaccine candidate 0 None
2009-07-28 New drug promises to reduce damage from a heart attack 0 2
2009-07-28 Deferoxamine could help diabetics heal wounds 0 None
2009-07-27 Seattle Genetics starts Brentuximab Vedotin retreatment trial 0 None
2009-07-22 H1N1 death toll doubles over last month; first vaccine trial begins 0 None
2009-07-22 NIAID to launch 2009 H1N1 influenza vaccine trials 0 None
2009-07-22 Hepatitis C infection: Treatment options equally effective, likelihood of success known early on 0 None
2009-07-21 Miglustat shows promise for cystic fibrosis 0 4.5
2009-07-21 Onchocerciasis elimination feasible with ivermectin treatment 0 None
2009-07-20 South Africa launches HIV/AIDS vaccine trial 0 None
2009-07-19 Preliminary findings in Phase IIA trial point to natural compound NIC5-15's potential in Alzheimer's disease 0 None
2009-07-19 TGF beta blocker prevents epilepsy following traumatic brain injury 0 3
2009-07-17 Thalidomide does not improve survival in small cell lung cancer 0 None
2009-07-16 Sunitinib shows promise for advanced kidney cancer patients with poor prognosis 0 None
2009-07-16 Improved bone healing with osteoporosis drug teriparatide 0 None
2009-07-15 Schering-Plough expands Vicriviroc study in treatment-naive patients with HIV 0 None
2009-07-12 Results from trials of DHA in Alzheimer's and age-related cognitive decline 0 None
2009-07-07 Thiarabine shows promise for rheumatoid arthritis 0 None
2009-07-07 Multaq approved for atrial fibrillation by FDA 2 None
2009-07-07 The effects of antimicrobial therapy on bacterial vaginosis in non-pregnant women 0 None
2009-07-07 Artemisinin-based combination therapy for treating uncomplicated malaria 0 None
2009-07-06 PATRICIA trial shows HPV vaccine effective in prevention of cervical lesions 0 None
2009-07-06 Antidepressants aid electroconvulsive therapy in treating severe depression 0 5
2009-07-02 Question marks on credibility of some published clinical trials 0 4.5
2009-07-01 Moxidectin being tested for onchocerciasis 0 2
2009-06-28 Golimumab shows promise for rheumatoid arthritis 1 5
2009-06-28 Inhaled growth hormone safe for children deficient in this key protein 0 3
2009-06-23 Clinical trial raises hope for Australian diabetics to be insulin free 0 4.5
2009-06-18 Seattle Genetics starts trial of SGN-35 for anaplastic large cell lymphoma 0 None
2009-06-18 Antisense Therapeutics trial of ATL1101 in prostate cancer shows promise 0 1
2009-06-18 Globe and Mail examines GlaxoSmithKline's RTS,S malaria vaccine trials in Kenya 0 None
2009-06-17 Cholesterol-lowering statin drugs do not lower risk of pneumonia in seniors 0 None
2009-06-17 Trial of new ‘combo’ treatment for hepatitis C 0 None
2009-06-16 Topical fluorouracil may improve appearance of aging skin 0 5
2009-06-16 Pneumococcal vaccine effective in preventing severe pneumonia 0 5
2009-06-09 Antiretroviral therapy earlier yields better clinical outcomes 0 3
2009-06-09 Novel diabetes treatment Syncria (albiglutide) improves glucose control and reduces weight 0 2.7
2009-06-09 Botox injections can help overactive bladders sufferers 0 5
2009-06-09 Cisplatin doubles lung cancer survival time in mice 0 None
2009-06-05 HCV protease inhibitor telaprevir improves response, halves treatment time for hepatitis C patients 1 None
2009-06-05 Tuberculosis booster vaccine trials to begin next month In South Africa 0 None
2009-06-04 Experimental drug five times more effective against MDR-TB than conventional therapy 0 None
2009-06-02 Trial results show better survival for gallbladder and bile duct cancer 0 None
2009-06-01 Study to evaluate ‘Active Hexose Correlated Compound’ and the swine flu virus 0 None
2009-06-01 Vandetanib shows clinical benefit when combined with docetaxel for lung cancer 0 None
2009-06-01 Citalopram no more effective than a placebo for children with autism spectrum disorders 0 None
2009-06-01 Bayer announces new data on novel anti-cancer compound 0 None
2009-06-01 Blood pressure drug reverses liver damage 0 None
2009-05-31 Iressa (gefinitib) chemotherapy combination proves safe for head and neck cancer patients 0 None
2009-05-31 Combination of temsirolimus and bryostatin appears safe and active in metastatic kidney cancer 0 None
2009-05-31 Blood-pressure medicine shown to reverse the effects of early-stage liver failure 0 None
2009-05-31 Catalyst Pharmaceutical Partners announces top-line results of CPP-109 phase II trial for cocaine addiction 0 None
2009-05-26 Abraxane prolongs survival in metastatic breast cancer 1 None
2009-05-26 Diabetes drug pioglitazone shows potential against multiple sclerosis 0 5
2009-05-25 Bioniche updates on phase III clinical trial with Urocidin in non-muscle-invasive bladder cancer 0 None
2009-05-22 Zyflamend, herb-based therapeutic shows promise for high risk of prostate cancer 0 None
2009-05-21 Aspirin and an anti-clotting drug ‘combo’ reduces risk of dialysis access failure 0 None
2009-05-21 ChemGenex’s Omacetaxine to be showcased in three oral oresentations at EHA 0 None
2009-05-20 Trial tests potential new angina treatment 0 None
2009-05-20 Sucampo Pharmaceuticals initiates phase 3 trial of Lubiprostone for chronic idiopathic constipation in Japan 0 None
2009-05-17 Sodium channel-blocking agent shows promise as a potential treatment for cystic fibrosis 0 None
2009-05-17 Pirfenidone shows promise for idiopathic pulmonary fibrosis 1 3
2009-05-17 Pregabalin shows potential as treatment for hot flashes 0 2.8
2009-05-14 Herpes drug Acyclovir does not reduce risk of HIV transmission, does slow HIV progression, study says 0 None
2009-05-12 Participants in antidepressant drug trials are atypical patients 0 None
2009-05-12 Schering-Plough starts patient enrollment in phase 3 trial for Acadesine 0 None
2009-05-07 Merck Serono starts second phase III trial of Safinamide in advanced Parkinson's 0 None
2009-05-07 Amsterdam Molecular Therapeutics commences preregistration trial for Glybera 0 None
2009-05-06 Metoclopramide versus droperidol for extreme nausea, vomiting during pregnancy 0 4
2009-05-04 New anticonvulsant compound prevents seizure progression in model of epilepsy 0 None
2009-04-30 A negative mGluR5 allosteric modulator shows efficacy in treating acute migraine attacks 0 None
2009-04-30 Histone deacetylase inhibitors show promise against head and neck cancer 0 None
2009-04-29 Pregabalin shows potential for restless legs syndrome - improves sleep 0 None
2009-04-29 Anti-viral drug telaprevir improves response, halves duration of hepatitis C treatment 1 None
2009-04-29 Many Black teens consider themselves victims of racial discrimination 0 None
2009-04-27 Ferring Pharmaceuticals launches new trial of Degarelix for intermittent androgen deprivation therapy 1 None
2009-04-27 Coadministration of paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells 0 None
2009-04-26 Roche and Pharmasset start phase IIb clinical trial of R7128 nucleoside polymerase inhibitor for chronic hepatitis C 1 None
2009-04-26 New lidocaine-prilocaine spray may treat premature ejaculation 0 1
2009-04-23 Trial of unique malaria vaccine candidate to begin 0 None
2009-04-22 Sorafenib and vitamin K combo shows anti-tumor effects in pancreas cancer, hepatocellular carcinoma 0 None
2009-04-22 Seattle Genetics presents new data on antibody-drug conjugate 0 None
2009-04-22 FDA gives 'go ahead' for phase II clinical trials of Bryostatin for the treatment of Alzheimer's disease 2 None
2009-04-22 AcelRx starts cancer breakthrough pain program 0 None
2009-04-22 AEterna Zentaris presents results for AEZS-112 in advanced cancer and lymphoma 0 None
2009-04-22 Combination of two chemotherapy drugs shows promise against recurrent gynecologic cancers 0 None
2009-04-22 Novel microparticle-based immune response modifier shows broad effects against recurrent or metastatic cancer 0 None
2009-04-20 NanoBio starts clinical trial for adjuvanted intranasal flu vaccine 0 4
2009-04-20 Ardea Biosciences announces positive results from a phase 1 study of lead candidate for hyperuricemia and gout 0 None
2009-04-20 Study looks at shikonin for human gastric adenocarcinoma 0 None
2009-04-20 Naltrexone appears to relieve fibromyalgia pain 2 4.7
2009-04-15 Topical bevacizumab therapy effective in treating corneal blood vessels growth that can cause blindness 0 4
2009-04-15 Mycophenolate mofetil may be an alternative therapy for lupus nephritis 0 None
2009-04-14 Experimental insulin-like growth factor receptor inhibitor a clear clinical candidate for pancreatic cancer therapy 0 None
2009-04-14 Oral etoricoxib provides pain relief after surgery 0 None
2009-04-13 Pharmacyclics starts clinical trial of novel oral Btk inhibitor for refractory B-cell non-Hodgkin's lymphoma 0 None
2009-04-12 Treatment for acid reflux does not improve asthma symptoms 0 None
2009-04-09 Serentis begins trial with first-in-class SRD441 for eczema 0 None
2009-04-09 Clinical trials for two compounds show promise in advanced prostate cancer 0 None
2009-04-09 Experimental drug lowers PSA levels 0 None
2009-04-08 New therapy for metastatic prostate cancer shows promise 0 None
2009-04-08 Trial of new biologic agent to treat psoriatic arthritis 0 None
2009-04-08 Intercell starts trial for Streptococcus pneumoniae vaccine candidate 0 None
2009-04-06 Experimental vaccine shows promise for the treatment of early lung cancer 0 None
2009-04-06 Celsion announces promising trial results for ThermoDox in breast cancer 0 None
2009-04-06 Avastin safe and effective at delaying tumor progression 0 None
2009-04-02 Is telmisartan effective in treating non-alcoholic steatohepatitis? 0 None
2009-04-02 Bionovo announces publication of positive phase 2 trial results for Menerba 0 5
2009-04-02 Aerovance starts phase IIb clinical trial with Aerovant for uncontrolled asthma 0 None
2009-04-01 Sorafenib may help patients suffering from advanced portal hypertension 0 None
2009-04-01 Pharmaxis reaches milestone in cystic fibrosis trial 0 None
2009-03-31 ImQuest presents data on the anti-hepatitis B virus activity of Pyrimidinediones 0 None
2009-03-31 New smoking cessation drug varenicline tartrate shows promise in trials 0 None
2009-03-30 SARcode announces results of phase 1 trial of SAR 1118 ophthalmic solution in healthy adult subjects 0 None
2009-03-30 Corthera's Relaxin in acute heart failure shows promising results 0 None
2009-03-30 Nile Therapeutics update on phase II CD-NP trial for acute heart failure 0 None
2009-03-29 New Lantheus study finds significant survival benefit for critically ill patients undergoing contrast-enhanced echocardiography 0 None
2009-03-29 NTRILIPIX (fenofibric acid) in combo with Rosuvastatin calcium shows improvement on key lipids for cholesterol management 0 None
2009-03-29 Medgenics’ phase I/II clinical trial shows EPODURE continuous anemia treatment lasting 5 months in kidney disease patients 0 None
2009-03-29 Eli Lilly announces inconclusive study results for mGlu2/3 in acute schizophrenia 0 None
2009-03-29 ARCA biopharma presents data from phase 3 BEST trial of Gencaro 0 None
2009-03-29 Dapagliflozin trial results indicate improvement in key glycemic measures in treatment-naive type 2 diabetes 0 None
2009-03-29 CRESTOR found to reduced CV risk in patients achieving low LDL-C and hsCRP targets in new Jupiter analysis 0 None
2009-03-29 CRESTOR (rosuvastatin) shown to significantly reduce risk of venous thromboembolism 0 None
2009-03-29 A comparative analysis of four beta blocker trials 0 None
2009-03-29 ArunA Biomedical to commercialize human embryonic stem cell derived mesenchymal cells 0 None
2009-03-29 Amicus Therapeutics presents positive results from phase 2 extension study of Amigal for Fabry disease 0 None
2009-03-29 RegeneRx reports phase II venous stasis trial results 0 None
2009-03-29 Positive phase 3 uveitis trial results for voclosporin 0 None
2009-03-29 Add-on treatment may reduce treatment-associated weight gain caused by antipsychotic treatments 0 None
2009-03-26 Oxycodone effective against shingles pain 0 None
2009-03-24 Rexahn Pharmaceuticals starts phase II pancreatic cancer trial 0 None
2009-03-24 Radius starts Ppase 2a trial of RAD1901 in menopausal hot flashes 0 None
2009-03-24 Orexo reports on efficacy study in allergic rhinitis with OX914 0 None
2009-03-24 Gilead commences phase II trial of Cicletanine for pulmonary arterial hypertension 0 None
2009-03-24 Canadian researchers to launch clinical trial to determine efficacy of treating latent TB with four-month course of Rifampin 0 None
2009-03-24 Phase II clinical trial of tuberculosis vaccine candidate to begin next month in South Africa 0 None
2009-03-23 Review of probiotics in the treatment of Irritable Bowel Syndrome 0 None
2009-03-23 NEJM Letters respond to recent studies on malaria vaccines, treatments 0 None
2009-03-22 Cathepsin B increases apoptosis in fulminant hepatic failure 0 None
2009-03-20 SemBioSys Genetics announces clinical results with plant-produced insulin 0 None
2009-03-20 Potential colon cancer being tested 0 None
2009-03-17 Drug pactimibe does not appear to reduce progression of atherosclerosis 0 None
2009-03-17 Cephalon announces positive results from study of NUVIGIL in bipolar depression 0 None
2009-03-17 Alba Therapeutics announces next clinical trial of lead compound, Larazotide Acetate 0 None
2009-03-16 Budesonide nasal wash shows promise for chronic rhinosinusitis 0 4.3
2009-03-16 Trial of new combination treatment targeting hormone receptor-positive locally advanced breast cancer 0 None
2009-03-16 Helix BioPharma receives approval to start phase II study of topical interferon alpha-2b in low-grade cervical lesions 0 None
2009-03-16 Healthpoint intiates phase II clinical trial to evaluate effectiveness of HP802-247 in venous leg ulcers 0 None
2009-03-15 Nobilon's intranasal influenza vaccine begins phase I clinical development 0 None
2009-03-12 Schering-Plough's investigational oral thrombin receptor antagonist meets primary endpoint in a newly published study 0 None
2009-03-12 Biothera receives approval to launch two lung cancer trials 0 None
2009-03-12 BioCis Pharma starts trial of novel topical drug for dermatology 0 None
2009-03-11 Rituximab may be effective in treating membranous nephropathy 0 None
2009-03-11 Study of Rituxan (rituximab) in lupus nephritis misses primary endpoint 0 5
2009-03-11 Rituximab useful for advanced indolent lymphoma 0 None
2009-03-10 Long-term effects of two common drugs for early Parkinson's similar 0 None
2009-03-05 Vaginal microbicide gel shows promise as HIV prevention method for women 0 None
2009-03-04 Rituximab reduces kidney inflammation in patients with severe lupus nephritis 0 None
2009-03-03 Pharmaxis announces NDA filing for Aridol 0 None
2009-03-03 Trial looks at telmisartan in treating non-alcoholic steatohepatitis 0 None
2009-03-03 Bionovo announces publication of positive trial results for Menerba 0 None
2009-03-03 Aerovance starts trial of Aerovant for uncontrolled asthma 0 None
2009-03-03 Type 1 diabetes patients sought for UT Southwestern clinical drug trial 0 None
2009-03-02 Angiogenesis inhibitors, study points to limitations, solutions 0 None
2009-03-02 Biphasic insulin provides significant improvements in more than 52,000 diabetic patients 0 None
2009-03-02 Chantix side effects no worse for people with history of depression 0 2
2009-03-01 Experimental drug fampridine improves mobility for some MS patients 1 5
2009-02-26 Lab tests show meropenem and clavulanate combination effective against drug-resistant TB bacteria 0 1.5
2009-02-25 Medivation announces new positive efficacy data from trial of MDV3100 in Castration-resistant prostate cancer 0 None
2009-02-24 Goserelin improves long-term survival in premenopausal women with early breast cancer 0 None
2009-02-23 Bavarian Nordic updates on breast cancer vaccine studies 0 5
2009-02-22 Neuralstem's ALS trial on hold 0 None
2009-02-20 Questions of ethics and quality cloud globalization of clinical trials 0 None
2009-02-20 Optimizing dosage of blood-thinning drug warfarin 0 None
2009-02-20 Drug sodium phenylbutyrate could improve the memory of those with Alzheimer's disease 0 None
2009-02-18 Ondansetron shown to be a viable treatment option for opioid addiction 1 5
2009-02-18 GlaxoSmithKline starts phase III trial of Syncria (albiglutide) type 2 diabetes medication 0 None
2009-02-16 Experimental antiarrhythmic drug dronedarone reduces death rate in patients with atrial fibrillation 0 2
2009-02-16 New trial targets kidney cancer drug sorafenib in bladder cancer 0 None
2009-02-16 Avosentan shows prmoise for diabetic kidney disease 0 None
2009-02-15 Trial of Quadramet (153 Samarium-lexidronam) in combo with Velcade shows positive results 0 None
2009-02-11 Study on ustekinumab for treatment of psoriatic arthritis published 0 None
2009-02-11 Candesartan cilexetil reduces proteinuria in kidney disease patients 0 4
2009-02-10 ViroPharma reports results of trial for Maribavir in bone marrow transplant patients 0 None
2009-02-08 Atorvastatin and lovastatin found to be ineffective for breast cancer prevention 0 None
2009-02-05 Study tests salsalate anti-inflammatory for poorly controlled type 2 diabetes 0 None
2009-02-05 Sangamo BioSciences starts trial of CCR5-ZFP therapeutic to treat HIV/AIDS 1 None
2009-02-05 Safinamide significantly improved motor function in patients with advanced Parkinson's disease 0 4
2009-02-02 Fasudil could reduce risk of Alzheimer's 0 None
2009-02-02 Sedative dexmedetomidine may offer advantages over agents often used for sedation in ICU 0 None
2009-02-02 Antiepileptic drug vigabatrin may decrease spasms for infants with epilepsy 0 None
2009-02-02 Century old drug clofazimine shows potential for multiple sclerosis 0 None
2009-02-02 Infliximab after intestinal resective surgery may help prevent post-op Crohn's disease recurrence 0 None
2009-01-29 Study of cannabinoid medicine for pain found patients got 'high,' but effects not related to pain relief 0 None
2009-01-29 Leconotide, an investigative calcium channel blocker, shows potential as pain treatment 0 None
2009-01-27 Early treatment with rasagiline (Azilect) for Parkinson's best 1 5
2009-01-23 Lisofylline drug improves type 2 insulin action; reduces harm of fat in preclinical study 0 None
2009-01-19 Cream containing tretinoin associated with death in clinical trial, but relationship does not appear causal 0 5
2009-01-19 Pre-emptive treatment helped curtail skin toxicity with Panitumumab 0 None
2009-01-19 Combo malaria treatment dihydroartemisinin and piperaquine shows promise 0 None
2009-01-15 Algeta completes phase II trial with Alpharadin for treating bone metastases in advanced prostate cancer 0 None
2009-01-09 Discovery of better treatment for bacterial pneumonia 0 5
2009-01-08 New nasal spray vaccine shown to be effective against botulism 0 None
2009-01-06 Active Hexose Correlated Compound shown to enhances immune system by increasing production of key dendritic cells 0 None
2009-01-06 Sequella, Inc. drug compound SQ109 selected for phase 1B clinical trial program 0 None
2009-01-06 New drug being tested for Fragile X syndrome 1 4
2009-01-06 Phase III studies of EXPAREL (DepoBupivacaine) from Pacira complete enrollment 0 None
2009-01-06 Clioquinol - gastrointestinal drug could become anti-aging treatment 0 None
2009-01-06 Nicotine gum effective for gradual smoking reduction and cessation 0 None
2009-01-06 Chimerix completes phase I study and starts phase II multi-dose trial for CMX001 0 None
2009-01-06 Novel compound F15845 shows promise for angina 1 None
2009-01-06 Novel treatment option for obesity 0 None
2009-01-05 Phase 3 trial begins for Gammagard liquid plus rHuPH20 in primary immunodeficiency patients 0 None
2009-01-05 Molecular insight into how a heart failure drug in clinical trials works 0 None
2009-01-05 Cylene Pharmaceuticals starts CX-4945 trial - first-in class inhibitor of CK2 0 None
2009-01-01 Candesartan shown to be safe new therapy for genetic heart disease 0 None

Total

1179 posts
40 comments
241 raters